Dilated Cardiomyopathy 2A

Genetic MONDO:0012746 Pathograph 12 Show in embeddings browser Dilated Cardiomyopathy Genetic Disorder

Dilated cardiomyopathy 2A (CMD2A) is the autosomal recessive, TNNI3-related form of familial isolated dilated cardiomyopathy. TNNI3 encodes cardiac troponin I (cTnI), the inhibitory subunit of the sarcomeric troponin complex that holds the actin-tropomyosin thin filament in its "off" state until calcium binding to troponin C releases the inhibition and permits cross-bridge cycling. CMD2A is caused by biallelic loss-of-function (mainly protein-truncating, and rarely splice-disrupting or whole-gene-deletion) TNNI3 genotypes, and it is mechanistically distinct from the far more common heterozygous TNNI3 missense disease that produces autosomal dominant hypertrophic (CMH7) and restrictive (RCM1) cardiomyopathy. Its most characteristic feature is a developmentally timed onset: the fetal and neonatal heart expresses slow skeletal troponin I (ssTnI, TNNI1) instead of cTnI, so a cTnI-null heart is protected until the perinatal TnI isoform switch withdraws that substitute. Affected children are therefore typically well at birth and then decompensate in the neonatal period or first months of life with severe left ventricular dilation, profoundly reduced ejection fraction, and refractory heart failure; one reported consanguineous kindred lost three infant siblings, and the natural history without transplantation is frequently lethal in the first year or two. Heterozygous carriers, including the parents in consanguineous kindreds, are typically unaffected or show only low-penetrance disease. ClinGen's Dilated Cardiomyopathy Gene Curation Expert Panel classifies the autosomal recessive TNNI3-DCM relationship as Strong, separately from its Strong autosomal dominant TNNI3-DCM classification. The degree of residual cTnI appears to set the phenotype within the recessive allelic series: complete absence gives dilated cardiomyopathy, whereas a more distal truncation retaining partial function has been reported to give pediatric restrictive cardiomyopathy instead.

Ask OpenScientist

Ask a research question about Dilated Cardiomyopathy 2A. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

1
Inheritance
4
Pathophys.
8
Phenotypes
2
Hypotheses
3
Gaps
12
Pathograph
1
Genes
4
Variants
4
Medical Actions
3
Differentials
1
Models
1
References
1
Deep Research
🏷

Classifications

Harrison's Part
CARDIOVASCULAR GENETICS ENVIRONMENT DISEASE
👪

Inheritance

1
Autosomal Recessive HP:0000007
CMD2A is transmitted as an autosomal recessive trait: affected individuals carry two loss-of-function TNNI3 alleles (homozygous in consanguineous families, compound heterozygous otherwise), while heterozygous parents and relatives are typically unaffected or show only low-penetrance disease. This recessive mode is what distinguishes CMD2A from the dominant TNNI3 cardiomyopathies, and TNNI3 was the first gene shown to cause dilated cardiomyopathy in this manner.
Autosomal recessive inheritance
Show evidence (3 references)
PMID:15070570 SUPPORT Human Clinical
"TNNI3 is the first recessive gene identified for this condition, and we suggest that other such genes could be pinpointed by mutation analyses designed to identify homozygous mutations."
The founding CMD2A report explicitly establishes TNNI3 as a recessive dilated cardiomyopathy gene.
CGGV:assertion_b89182f6-1574-48c6-832f-add41ffbaa4c-2025-04-18T160000.000Z SUPPORT Other
"TNNI3 | HGNC:11947 | dilated cardiomyopathy | MONDO:0005021 | AR | Strong"
ClinGen's Dilated Cardiomyopathy Gene Curation Expert Panel records an autosomal recessive TNNI3-DCM gene-disease relationship with Strong clinical validity, curated separately from the dominant relationship.
PMID:38924380 SUPPORT Human Clinical
"We identified a homozygous frameshift variant in the TNNI3 gene (c.204delG; p.(Arg69AlafsTer8))."
Homozygosity for a truncating TNNI3 allele in a consanguineous family with three affected infant siblings and unaffected parents — the canonical recessive pedigree structure.
◈

Mechanistic Hypotheses

2
cTnI-null / perinatal TnI isoform-switch model
tnni3_null_isoform_switch_model CANONICAL
Evidence balance 1 support
The canonical model holds that biallelic TNNI3 loss-of-function abolishes cardiac troponin I, and that the resulting disease is timed by the developmental troponin I isoform switch. In fetal and neonatal myocardium the slow skeletal isoform (ssTnI, TNNI1) occupies the troponin complex and substitutes functionally for cTnI, so a cTnI-null heart develops and is born structurally normal. ssTnI is then downregulated on its own developmental schedule regardless of whether cTnI is available to replace it, and the heart is left globally troponin I-deficient. Thin-filament regulation fails — sarcomeres shorten, resting (diastolic) tension rises, and myofilament calcium sensitivity under activating conditions falls — giving an abrupt, severe, and frequently lethal heart failure in the neonatal period or first months of life. The Tnni3-null mouse reproduces exactly this time course.
Pathograph links
Biallelic TNNI3 Loss of Function -> Perinatal Troponin I Isoform Switch and Loss of ssTnI Compensation DIRECT A cTnI-null heart is only unmasked once the fetal isoform that has been standing in for cTnI is withdrawn.
Perinatal Troponin I Isoform Switch and Loss of ssTnI Compensation -> Thin-Filament Regulatory Failure and Impaired Myofilament Mechanics DIRECT
Thin-Filament Regulatory Failure and Impaired Myofilament Mechanics -> Left Ventricular Dilation and Systolic Failure DIRECT
Show evidence (1 reference)
PMID:9915769 SUPPORT Model Organism
"Mice lacking cardiac troponin I were born healthy, with normal heart and body weight, because a fetal troponin I isoform (identical to slow skeletal troponin I) compensated for the absence of cardiac troponin I. Compensation was only temporary, however, as 15 days after birth slow skeletal..."
Directly demonstrates the isoform-switch timing that is the core of this model: normal birth under ssTnI cover, then decompensation when ssTnI is withdrawn.
Residual-cTnI-dose model of dilated versus restrictive phenotype
tnni3_residual_function_phenotype_model EMERGING
Evidence balance 1 support
An emerging refinement proposes that within the recessive TNNI3 allelic series it is the amount of residual cTnI function, not simply the presence of biallelic truncation, that determines whether the child develops dilated or restrictive cardiomyopathy. Complete absence of cTnI produces the systolic, dilated phenotype of CMD2A; a more distal nonsense allele that leaves a partially functional (though reduced-abundance) protein has been reported to produce severe pediatric restrictive cardiomyopathy instead. If correct, the recessive TNNI3 phenotype is a graded function of residual protein rather than a binary null state, and the CMD2A/RCM boundary is set by truncation position.
Show evidence (1 reference)
PMID:41918167 SUPPORT Human Clinical
"In myocardial biopsies of the patient, TNNI3 protein abundance was diminished, suggesting that residual TNNI3 function may underlie RCM, while TNNI3 absence causes DCM."
States the residual-function hypothesis explicitly and supplies the myocardial-biopsy protein-abundance observation it rests on. Marked EMERGING because it currently rests on a single reported patient.
?

Discussions and Knowledge Gaps

3
Should CMD2A be curated as its own dismech entity, given that ClinGen curates the TNNI3 relationship against the generic "dilated cardiomyopathy" entity (MONDO:0005021) and splits it only by mode of inheritance, while MONDO maintains a distinct CMD2A node (MONDO:0012746)?
INTERPRETATION OPEN cmd2a_mondo_node_versus_clingen_lumped_dcm
Attached to
pathophysiology#Biallelic TNNI3 Loss of Function
ClinGen's Dilated Cardiomyopathy GCEP issued two separate TNNI3-DCM assertions on the same day, differing only in mode of inheritance (AD Strong, AR Strong), both against MONDO:0005021 — it treats the recessive relationship as a distinct curatable claim but not as a distinct disease entity. MONDO instead assigns CMD2A its own node with its own OMIM anchor. dismech follows MONDO here, and the substantive justification is mechanistic rather than nomenclatural: the recessive entity has a different molecular lesion (complete loss of function versus dominant-negative/altered-function missense), a different age of onset governed by a developmental isoform switch, and a different natural history. If ClinGen or MONDO later converges on a single lumped TNNI3-cardiomyopathy entity, this entry should be revisited rather than duplicated against its dominant siblings.
Show evidence (1 reference)
CGGV:assertion_b89182f6-1574-48c6-832f-add41ffbaa4c-2025-04-18T160000.000Z SUPPORT Other
"TNNI3 | HGNC:11947 | dilated cardiomyopathy | MONDO:0005021 | AR | Strong"
Shows that ClinGen curates the recessive relationship against the generic DCM entity rather than against the CMD2A node, which is the tension this discussion records.
Does truncation position within TNNI3 determine whether a biallelic loss-of-function genotype produces dilated or restrictive cardiomyopathy, and if so where is the boundary?
KNOWLEDGE GAP OPEN cmd2a_truncation_position_phenotype_boundary
Attached to
pathophysiology#Thin-Filament Regulatory Failure and Impaired Myofilament Mechanics
The recessive TNNI3 series is currently modeled as producing dilated cardiomyopathy, but a homozygous distal nonsense allele (p.Arg136*) with diminished-but-detectable myocardial protein has been reported to produce restrictive cardiomyopathy instead. That single observation implies a graded residual-function relationship rather than a binary null state, but it is one patient, the protein-abundance measurement is semiquantitative, and no systematic genotype-to-phenotype series across truncation positions exists. Until it does, dismech should not assert a positional rule.
Proposed experiments
Multi-center biallelic TNNI3 truncation-position genotype-phenotype series
exp_cmd2a_truncation_position_genotype_series
Assemble a multi-center series of biallelic TNNI3 loss-of-function patients annotated by truncation position, cardiomyopathy subtype, and age of onset, to test whether phenotype tracks predicted residual protein length.
Quantification of residual cTnI across recessive truncating alleles
exp_cmd2a_residual_ctni_quantification
Quantify cTnI protein abundance and thin-filament incorporation in myocardial tissue or patient-derived iPSC-cardiomyocytes across the reported truncating alleles, to establish whether residual function is measurable rather than inferred.
Show evidence (1 reference)
PMID:41918167 SUPPORT Human Clinical
"Overall, recessive TNNI3 protein truncation causes severe pediatric RCM, suggesting that the allelic status, type of genetic alteration, and length of TNNI3 protein truncation determine cardiomyopathy onset and subtype manifestation."
States the proposed positional rule as a suggestion drawn from a single patient — the open question this discussion records.
Does the murine slow-skeletal-troponin-I compensation-then-withdrawal mechanism, which supplies the timing explanation for CMD2A, actually operate on the same schedule in the human heart?
HUMAN MODEL MISMATCH OPEN cmd2a_sstni_compensation_human_fidelity
Attached to
pathophysiology#Perinatal Troponin I Isoform Switch and Loss of ssTnI Compensation
The isoform-switch explanation for why a cTnI-null child is well at birth and fails weeks later rests almost entirely on the Tnni3-null mouse, where the schedule is sharp and well characterized (ssTnI decline from day 15, death on day 18). The human TnI isoform switch is known to occur perinatally, but no direct measurement of ssTnI persistence in the myocardium of a CMD2A patient has been reported, and the human presentation window is broader — neonatal in some reports, later in the first year in others. Whether that variability reflects individual differences in the timing of ssTnI withdrawal, residual cTnI from hypomorphic alleles, or unrelated modifiers is unresolved. This is a model-fidelity question, not an absence of evidence: the mouse result is strong, its human transferability is the open item.
Proposed experiments
Myocardial ssTnI/cTnI abundance across CMD2A patient ages
exp_cmd2a_human_myocardial_sstni_timing
Measure ssTnI and cTnI protein abundance in myocardial tissue obtained at transplantation or autopsy from CMD2A patients of differing ages, to test whether clinical decompensation coincides with ssTnI withdrawal.
TnI isoform schedule in TNNI3-null human iPSC-cardiomyocytes
exp_cmd2a_ipsc_tni_isoform_schedule
Track TnI isoform composition during maturation of TNNI3-null iPSC-cardiomyocytes or engineered heart tissue against isogenic controls, to establish the human schedule in a controlled system.
Show evidence (2 references)
PMID:9915769 SUPPORT Model Organism
"Compensation was only temporary, however, as 15 days after birth slow skeletal troponin I expression began a steady decline, giving rise to a troponin I deficiency."
Supplies the precise murine schedule whose human counterpart has not been directly measured.
PMID:26526134 SUPPORT Other
"which are expressed under muscle type-specific and developmental regulations"
Confirms that TnI isoform expression is developmentally regulated in vertebrates generally. PARTIAL because it does not supply a human myocardial timing measurement.
⚙

Pathophysiology

4
Biallelic TNNI3 Loss of Function
TNNI3 encodes cardiac troponin I, the inhibitory subunit of the troponin complex and one of the three regulatory proteins (with troponin C and troponin T) that confer calcium sensitivity on the sarcomeric thin filament. CMD2A arises when both TNNI3 alleles are inactivated — most often by nonsense or frameshift variants (p.Arg69Alafs*8, p.Arg98*), but also by a synonymous variant creating a cryptic splice site with intron retention in trans with a whole-gene deletion. The lesion is a true loss of function rather than the dominant-negative or altered-function mechanism that characterizes the heterozygous TNNI3 missense variants responsible for hypertrophic and restrictive cardiomyopathy, which is why the disease is recessive and heterozygous carriers are largely spared.
cTnI-null / perinatal TnI isoform-switch model
Cardiomyocyte CL:0000746 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves Cardiomyocyte, annotated with cardiac muscle cell (CL:0000746). CL:0000746 is a cell type from the Cell Ontology.
TNNI3 hgnc:11947 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves TNNI3 (hgnc:11947). hgnc:11947 is a gene from the HUGO Gene Nomenclature Committee.
Regulation of cardiac muscle contraction GO:0055117 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves abnormal Regulation of cardiac muscle contraction (GO:0055117). GO:0055117 is a biological process from the Gene Ontology. ⚠ ABNORMAL
actin binding GO:0003779 Gene Ontology (GO) Relation: this pathophysiological event involves this molecular function This pathophysiological event involves decreased actin binding (GO:0003779). GO:0003779 is a molecular function from the Gene Ontology. ↓ DECREASED
troponin complex GO:0005861 Gene Ontology (GO) Relation: this pathophysiological event involves this cellular component This pathophysiological event involves abnormal troponin complex (GO:0005861). GO:0005861 is a cellular component from the Gene Ontology.
Myocardium UBERON:0002349 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in Myocardium (UBERON:0002349). UBERON:0002349 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
Perinatal Troponin I Isoform Switch and Loss of ssTnI Compensation A cTnI-null heart is only unmasked once the fetal isoform that has been standing in for cTnI is withdrawn. cTnI-null / perinatal TnI isoform-switch model
Show evidence (3 references)
PMID:26526134 SUPPORT Other
"Troponin I (TnI) is the inhibitory subunit of the troponin complex in the sarcomeric thin filament of striated muscle and plays a central role in the calcium regulation of contraction and relaxation."
Establishes the normal function of troponin I — thin-filament inhibition and calcium regulation of contraction and relaxation — that biallelic TNNI3 loss abolishes. Evidence source is OTHER because this is a structure-function review.
PMID:36981019 SUPPORT Human Clinical
"In recent years, however, an increasing amount of evidence has validated the hypothesis that biallelic TNNI3 null mutations cause a severe form of neonatal dilated cardiomyopathy."
States the causal claim of this node: biallelic TNNI3 null genotypes, not heterozygous missense change, are what produce this disease.
PMID:15070570 SUPPORT Human Clinical
"We identified a novel TNNI3 mutation in a family with recessive disease."
The founding human observation of a recessive TNNI3 genotype segregating in a family. Deliberately trimmed to the clinical sentence: the paper's accompanying functional-studies result is in vitro and is modeled as a separate IN_VITRO evidence item on the thin-filament node, so that one item is not tagged with two source types.
Perinatal Troponin I Isoform Switch and Loss of ssTnI Compensation
The heart expresses two troponin I isoforms under developmental control: the slow skeletal isoform (ssTnI, TNNI1) in fetal and early postnatal myocardium, replaced by cardiac troponin I (cTnI, TNNI3) as the heart matures. In a cTnI-null heart, ssTnI initially occupies the troponin complex and supports normal development, normal birth weight, and normal cardiac structure at birth. Critically, ssTnI downregulation proceeds on its own developmental schedule and is not held back by the absence of cTnI, so the myocardium passes from ssTnI-supported regulation to no troponin I at all. This node explains the entity's most distinctive clinical feature — a well child who decompensates abruptly in the neonatal period or first months — and is why CMD2A is a disease of infancy rather than of adulthood like most sarcomeric cardiomyopathy.
cTnI-null / perinatal TnI isoform-switch model
Cardiomyocyte CL:0000746 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves Cardiomyocyte, annotated with cardiac muscle cell (CL:0000746). CL:0000746 is a cell type from the Cell Ontology.
Regulation of striated muscle contraction GO:0006942 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves absent Regulation of striated muscle contraction (GO:0006942). GO:0006942 is a biological process from the Gene Ontology. ∅ ABSENT
Experimental models
Tnni3-null (cardiac troponin I knockout) mouse OTHER The model's central result is the timing of ssTnI withdrawal in a cTnI-null background and the consequent onset of failure.
Downstream
Thin-Filament Regulatory Failure and Impaired Myofilament Mechanics cTnI-null / perinatal TnI isoform-switch model
Show evidence (2 references)
PMID:9915769 SUPPORT Model Organism
"The results show that (1) developmental downregulation of slow skeletal troponin I occurs even in the absence of cardiac troponin I and (2) the resultant troponin I depletion alters specific mechanical properties of myocardium and can lead to a lethal form of acute heart failure."
Establishes both halves of this node: ssTnI is withdrawn regardless of cTnI status, and the resulting global troponin I depletion is what causes lethal heart failure. Model organism evidence; the corresponding human claim is the neonatal-onset timing documented in the patient reports.
PMID:26526134 SUPPORT Other
"Vertebrate TnI has evolved into three isoforms encoded by three homologous genes: TNNI1 for slow skeletal muscle TnI, TNNI2 for fast skeletal muscle TnI and TNNI3 for cardiac TnI, which are expressed under muscle type-specific and developmental regulations."
Documents the developmentally regulated TnI isoform system on which the ssTnI-compensation mechanism depends. Evidence source is OTHER because this is a review.
Thin-Filament Regulatory Failure and Impaired Myofilament Mechanics
Without any troponin I, the thin filament loses the inhibitory element that normally keeps tropomyosin over the myosin-binding sites at low calcium and that transduces calcium binding at troponin C into cooperative filament activation. The measured consequence in troponin I-depleted ventricular myocytes is a combined systolic and diastolic defect: sarcomeres are shortened and resting tension is elevated under relaxing conditions, while myofilament calcium sensitivity is reduced under activating conditions. Contraction is therefore both incompletely switched off between beats and inefficiently switched on during systole, degrading net pump performance. In the recessive human allelic series the severity of this regulatory failure appears to track residual cTnI abundance.
cTnI-null / perinatal TnI isoform-switch model
Cardiac ventricular myocyte CL:0000746 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves Cardiac ventricular myocyte, annotated with cardiac muscle cell (CL:0000746). CL:0000746 is a cell type from the Cell Ontology.
Cardiac muscle contraction GO:0060048 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased Cardiac muscle contraction (GO:0060048). GO:0060048 is a biological process from the Gene Ontology. ↓ DECREASED Regulation of cardiac muscle cell contraction GO:0086004 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves abnormal Regulation of cardiac muscle cell contraction (GO:0086004). GO:0086004 is a biological process from the Gene Ontology. ⚠ ABNORMAL
Experimental models
Tnni3-null (cardiac troponin I knockout) mouse OTHER Isolated ventricular myocytes supply the sarcomere-length, resting-tension, and calcium-sensitivity measurements of troponin I depletion.
Downstream
Left Ventricular Dilation and Systolic Failure cTnI-null / perinatal TnI isoform-switch model
Show evidence (2 references)
PMID:9915769 SUPPORT Model Organism
"Ventricular myocytes isolated from these troponin I-depleted hearts displayed shortened sarcomeres and elevated resting tension measured under relaxing conditions and had a reduced myofilament Ca sensitivity under activating conditions."
Supplies the specific myofilament mechanics of troponin I depletion — elevated diastolic tension plus reduced calcium sensitivity — that this node asserts.
PMID:15070570 SUPPORT In Vitro
"Functional studies showed impairment of troponin interactions that could lead to diminished myocardial contractility."
Human-variant functional data linking the recessive TNNI3 lesion to impaired troponin interactions and reduced contractility. Classified IN_VITRO because the functional studies were biochemical assays of troponin interaction rather than patient observations.
Left Ventricular Dilation and Systolic Failure
The failing myofilament produces the defining organ-level phenotype: progressive left ventricular chamber enlargement with severely depressed ejection fraction, functional mitral regurgitation from annular dilation, and congestive heart failure. Reported infants have presented with left ventricular ejection fractions as low as 10%, and the resulting circulatory failure is what kills — one reported kindred lost three siblings in the first year of life. Because the primary lesion is a permanent absence of a structural regulatory protein rather than a modifiable stress, this node does not remit; neurohormonal therapy slows it but transplantation is the only definitive intervention.
Cardiomyocyte CL:0000746 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves Cardiomyocyte, annotated with cardiac muscle cell (CL:0000746). CL:0000746 is a cell type from the Cell Ontology.
Cardiac muscle contraction GO:0060048 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased Cardiac muscle contraction (GO:0060048). GO:0060048 is a biological process from the Gene Ontology. ↓ DECREASED
Left ventricle UBERON:0002084 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in Left ventricle, annotated with heart left ventricle (UBERON:0002084). UBERON:0002084 is an anatomical location from the Uberon multi-species anatomy ontology.
Show evidence (2 references)
PMID:38924380 SUPPORT Human Clinical
"The second infant presented a DCM phenotype with a severely reduced Left Ventricular Ejection Fraction (LVEF) of 10%."
Quantifies the depth of systolic failure produced by a biallelic truncating TNNI3 genotype.
PMID:36565796 SUPPORT Human Clinical
"The one-year-old girl presented severe left ventricular enlargement and significantly reduced left ventricular systolic function and she died of respiratory and heart failure soon after her diagnosis."
Documents the chamber dilation plus systolic dysfunction combination and its lethal outcome in a compound heterozygous TNNI3 patient.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Dilated Cardiomyopathy 2A Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

8
Cardiovascular 5
Dilated cardiomyopathy VERY_FREQUENT HP:0001644 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Dilated cardiomyopathy (HP:0001644), qualified as neonatal onset. HP:0001644 is a phenotype from the Human Phenotype Ontology.
Onset: NEONATAL
Show evidence (2 references)
PMID:36981019 SUPPORT Human Clinical
"biallelic TNNI3 null mutations cause a severe form of neonatal dilated cardiomyopathy"
Dilated cardiomyopathy is the obligate phenotype of the biallelic TNNI3 genotype and is characterized as neonatal in onset, supporting both the VERY_FREQUENT band and the NEONATAL onset category.
PMID:38924380 SUPPORT Human Clinical
"Here, we report a family with three deceased offspring at the age of 1 year old."
Documents infantile presentation and death in three affected siblings, showing that the onset window extends beyond the strictly neonatal period.
Reduced left ventricular ejection fraction VERY_FREQUENT HP:0012664 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Reduced left ventricular ejection fraction (HP:0012664), qualified as severity severe. HP:0012664 is a phenotype from the Human Phenotype Ontology.
Severity: SEVERE
Show evidence (1 reference)
PMID:38924380 SUPPORT Human Clinical
"Similarly, the third infant showed a severe DCM phenotype with LVEF of 30% as well, in addition to eccentric mitral insufficiency."
Quantifies severely reduced ejection fraction in a second affected sibling of the same consanguineous kindred.
Left ventricular systolic dysfunction VERY_FREQUENT HP:0025169 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Left ventricular systolic dysfunction (HP:0025169). HP:0025169 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:36565796 SUPPORT Human Clinical
"significantly reduced left ventricular systolic function"
Direct observation of systolic dysfunction in a patient with biallelic TNNI3 loss of function.
Congestive heart failure VERY_FREQUENT HP:0001635 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Congestive heart failure (HP:0001635), qualified as infantile onset. HP:0001635 is a phenotype from the Human Phenotype Ontology.
Onset: INFANTILE
Show evidence (1 reference)
PMID:36565796 SUPPORT Human Clinical
"she died of respiratory and heart failure soon after her diagnosis"
Heart failure as the terminal event in a one-year-old patient with biallelic TNNI3 loss of function, supporting both the phenotype and its infantile onset.
Sudden cardiac death HP:0001645 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Sudden cardiac death (HP:0001645). HP:0001645 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:36565796 SUPPORT Human Clinical
"Dilated cardiomyopathy type 2A (DCM2A, MIM: #611880) is a rare autosomal recessive heart disease leading to heart failure and sudden cardiac death."
Names sudden cardiac death as an outcome of DCM2A specifically. Frequency is deliberately omitted — no source quantifies the arrhythmic death rate in this entity.
PMID:26022819 SUPPORT Human Clinical
"The cumulative incidence of SCD at 15 years was 5% for dilated cardiomyopathy (DCM), 6% for hypertrophic cardiomyopathy (HCM), 12% for restrictive cardiomyopathy, and 23% for left ventricular (LV) noncompaction."
Supplies the background sudden-death risk for childhood dilated cardiomyopathy as a class. PARTIAL because the cohort is all childhood DCM, not the TNNI3 recessive subset.
Respiratory 1
Respiratory distress from pulmonary congestion OCCASIONAL Tachypnea HP:0002789 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Tachypnea (HP:0002789). HP:0002789 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:36565796 SUPPORT Human Clinical
"she died of respiratory and heart failure soon after her diagnosis"
Documents respiratory failure accompanying the cardiac failure in a biallelic TNNI3 patient. PARTIAL because the quote establishes respiratory compromise rather than tachypnea specifically.
Other 2
Left ventricular dilatation VERY_FREQUENT HP:4000141 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Left ventricular dilatation (HP:4000141). HP:4000141 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:36565796 SUPPORT Human Clinical
"The one-year-old girl presented severe left ventricular enlargement"
Direct observation of left ventricular cavity enlargement in a patient with biallelic TNNI3 loss of function.
Mitral regurgitation OCCASIONAL HP:0001653 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Mitral regurgitation (HP:0001653). HP:0001653 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:38924380 SUPPORT Human Clinical
"in addition to eccentric mitral insufficiency"
Documents mitral regurgitation accompanying the dilated phenotype. OCCASIONAL rather than a higher band because it is reported in one of the described siblings rather than as a consistent feature.
🧬

Genetic Associations

1
TNNI3 Biallelic Loss-of-Function Variants (Biallelic Loss-of-Function Variants)
Gene: TNNI3 hgnc:11947 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is TNNI3 (hgnc:11947). hgnc:11947 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: CAUSATIVE
Autosomal Recessive
Show evidence (4 references)
CGGV:assertion_b89182f6-1574-48c6-832f-add41ffbaa4c-2025-04-18T160000.000Z SUPPORT Other
"TNNI3 | HGNC:11947 | dilated cardiomyopathy | MONDO:0005021 | AR | Strong"
ClinGen's Dilated Cardiomyopathy Gene Curation Expert Panel classifies the autosomal recessive TNNI3-DCM gene-disease relationship as Strong under SOP10.
PMID:36981019 SUPPORT Human Clinical
"two unrelated patients afflicted with early onset dilated cardiomyopathy, due to homozygosity for the p.Arg98* TNNI3 variant, which had thus far been documented only in heterozygous patients and apparently healthy carriers, and the recurrent p.Arg69Alafs*8 variant, respectively"
Names both recurrent truncating alleles and records that p.Arg98* occurs in healthy heterozygous carriers — the key zygosity argument for a recessive mechanism.
PMID:36565796 SUPPORT Human Clinical
"a novel c.24G＞A (p.Ala8Ala) (NM_000363.4) in exon 2 and a deletion of entire gene"
Documents the compound heterozygous synonymous-plus-deletion genotype, and shows that a synonymous variant can be a CMD2A allele.
+ 1 more reference
Variants (4)
TNNI3 p.Arg69Alafs*8 (c.204delG)
Gene: TNNI3 hgnc:11947 HUGO Gene Nomenclature Committee (hgnc) Relation: this variant is in this gene This variant is in TNNI3 (hgnc:11947). hgnc:11947 is a gene from the HUGO Gene Nomenclature Committee.
Recurrent frameshift allele. Reported homozygous in a consanguineous Tunisian family with three infants who died at about one year of age, and independently in the review series of biallelic TNNI3 loss-of-function patients. Classified pathogenic by ACMG criteria.
Show evidence (1 reference)
PMID:38924380 SUPPORT Human Clinical
"This variant has been recently reported in the ClinVar database in association with cardiac phenotypes as pathogenic or likely pathogenic and classified as pathogenic according to ACMG."
Records the pathogenicity classification of the recurrent p.Arg69Alafs*8 allele.
TNNI3 p.Arg98*
Gene: TNNI3 hgnc:11947 HUGO Gene Nomenclature Committee (hgnc) Relation: this variant is in this gene This variant is in TNNI3 (hgnc:11947). hgnc:11947 is a gene from the HUGO Gene Nomenclature Committee.
Nonsense allele reported in the homozygous state in a patient with early-onset dilated cardiomyopathy, having previously been documented only in heterozygous patients and apparently healthy carriers — direct evidence that the heterozygous state is not equivalent to the biallelic one.
Show evidence (1 reference)
PMID:36981019 SUPPORT Human Clinical
"homozygosity for the p.Arg98* TNNI3 variant, which had thus far been documented only in heterozygous patients and apparently healthy carriers"
Establishes both the homozygous disease genotype and the prior observation of the same allele in unaffected heterozygotes.
TNNI3 c.24G>A (p.Ala8Ala)
Gene: TNNI3 hgnc:11947 HUGO Gene Nomenclature Committee (hgnc) Relation: this variant is in this gene This variant is in TNNI3 (hgnc:11947). hgnc:11947 is a gene from the HUGO Gene Nomenclature Committee.
Synonymous exon 2 variant that nonetheless abolishes function by creating a cryptic intron 2 splice donor, producing intron retention; found in trans with a deletion of the entire gene in a Chinese infant with severe dilated cardiomyopathy. Demonstrated by minigene splicing assay.
Show evidence (1 reference)
PMID:36565796 SUPPORT In Vitro
"Minigene splicing analyses showed it led to an intron retention (c.24 + 1_24 + 45ins) by intron 2 cryptic splicing."
Functional demonstration that this synonymous allele is loss-of-function via cryptic splicing.
TNNI3 p.Arg136* (c.406C>T)
Gene: TNNI3 hgnc:11947 HUGO Gene Nomenclature Committee (hgnc) Relation: this variant is in this gene This variant is in TNNI3 (hgnc:11947). hgnc:11947 is a gene from the HUGO Gene Nomenclature Committee.
More distal nonsense allele reported homozygous in a 2-year-old with severe pediatric restrictive rather than dilated cardiomyopathy, with diminished but detectable TNNI3 protein in myocardial biopsy. Included here as the boundary case of the recessive series that motivates the residual-function model.
Show evidence (1 reference)
PMID:41918167 SUPPORT Human Clinical
"a homozygous TNNI3 nonsense variant, c.406C>T (p.Arg136"
Identifies the distal nonsense allele and its homozygous state in the reported restrictive-phenotype patient. The snippet stops before the terminator glyph, which the source renders with a non-ASCII asterisk.
💊

Medical Actions

4
Guideline-Directed Heart Failure Pharmacotherapy
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: ACE inhibitor NCIT:C247 NCI Thesaurus (NCIT) Relation: this treatment uses this therapeutic agent This treatment uses ACE inhibitor (NCIT:C247). NCIT:C247 is a therapeutic agent from the NCI Thesaurus. beta-blocker NCIT:C29576 NCI Thesaurus (NCIT) Relation: this treatment uses this therapeutic agent This treatment uses beta-blocker, annotated with Beta-Adrenergic Antagonist (NCIT:C29576). NCIT:C29576 is a therapeutic agent from the NCI Thesaurus. mineralocorticoid receptor antagonist (spironolactone as the class exemplar) NCIT:C840 NCI Thesaurus (NCIT) Relation: this treatment uses this therapeutic agent This treatment uses mineralocorticoid receptor antagonist (spironolactone as the class exemplar), annotated with Spironolactone (NCIT:C840). NCIT:C840 is a therapeutic agent from the NCI Thesaurus.
Standard anti-remodeling heart-failure therapy — renin-angiotensin system blockade, a beta-blocker, and a mineralocorticoid receptor antagonist, dosed for age — targeting the neurohormonal amplifier between the myofilament lesion and adverse ventricular remodeling. There is no TNNI3-specific or troponin-replacing therapy, so management is the generic dilated-cardiomyopathy regimen, and in this entity it is frequently insufficient: reported infants have had refractory low ejection fraction despite treatment.
Mechanism Target:
INHIBITS Left Ventricular Dilation and Systolic Failure — Neurohormonal blockade slows adverse remodeling downstream of the myofilament defect; it does not address the absent troponin I.
Show evidence (2 references)
PMID:31073128 SUPPORT Other
"As DCM eventually leads to impaired contractility, standard approaches to prevent or treat heart failure are the first-line treatment for patients with DCM."
Establishes standard heart-failure therapy as first-line management for dilated cardiomyopathy, of which CMD2A is a genetic form. Evidence source is OTHER because this is a Nature Reviews Disease Primers review.
PMID:38089682 SUPPORT Human Clinical
"He presented repeated weaning difficulties during hospitalization with intractable low EF heart insufficiency."
Illustrates the refractoriness of neonatal TNNI3-associated dilated cardiomyopathy to supportive and medical management. PARTIAL because this patient carried a de novo heterozygous variant rather than a biallelic CMD2A genotype.
Mechanical Circulatory Support (ECMO and Ventricular Assist Device)
Action: mechanical circulatory support as a bridge to transplantationNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is mechanical circulatory support as a bridge to transplantation, annotated with Ventricular Assist Device Placement (NCIT:C80452). NCIT:C80452 is a clinical intervention from the NCI Thesaurus. Ontology label: Ventricular Assist Device Placement NCIT:C80452
The bridge between failing medical therapy and transplantation. When an infant with CMD2A decompensates into low-output failure or cardiogenic shock, veno-arterial extracorporeal membrane oxygenation provides emergency rescue and a ventricular assist device provides durable support until a donor organ is available. This step sits between guideline-directed pharmacotherapy and heart transplantation in the care pathway, and matters disproportionately in this entity because the disease presents in infancy with severe, refractory systolic failure and because transplantation is the only definitive option.
Mechanism Target:
INHIBITS Left Ventricular Dilation and Systolic Failure — Mechanical support substitutes for the failing ventricle's pump function. It does not touch the myofilament lesion; it buys time to transplant.
Show evidence (2 references)
PMID:42334151 SUPPORT Human Clinical
"Children with end-stage dilated cardiomyopathy (DCM) usually undergo heart transplantation or a short-term bridge with a ventricular assist device."
Establishes ventricular assist device support as the standard bridge step preceding transplantation in end-stage pediatric dilated cardiomyopathy. PARTIAL because the registry cohort is children aged 10-18 with DCM of any cause, not the infantile recessive TNNI3 subset.
PMID:42249650 SUPPORT Human Clinical
"A 12-year-old girl with recurrent cardiac arrests underwent emergency LVAD implantation (EXCOR® Active) for 6 h for bridging to HTx."
Documents emergency device implantation as a bridge to transplantation in a child with dilated cardiomyopathy and end-stage heart failure. PARTIAL because the reported patients are older children with DCM of unstated genetic cause rather than confirmed CMD2A.
Heart Transplantation
Action: heart transplantationNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is heart transplantation (NCIT:C15246). NCIT:C15246 is a clinical intervention from the NCI Thesaurus. Ontology label: Heart Transplantation NCIT:C15246
The only definitive therapy. Because the lesion is the permanent absence of a structural regulatory protein rather than a reversible insult, recovery of ventricular function is not expected, and transplantation is the endpoint for children who survive to reach it. In the recessive TNNI3 series, transplantation has been performed at 28 months for treatment-refractory disease.
Show evidence (1 reference)
PMID:41918167 SUPPORT Human Clinical
"The RCM in this patient was treatment refractory and resulted in a heart transplant at the age of 28 months."
Documents transplantation as the outcome of treatment-refractory recessive TNNI3 cardiomyopathy. PARTIAL because this patient's phenotype was restrictive rather than dilated.
Genetic Counseling and Reproductive Options
Action: genetic counselingNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is genetic counseling (NCIT:C15240). NCIT:C15240 is a clinical intervention from the NCI Thesaurus. Ontology label: Genetic Counseling NCIT:C15240
Counseling for a 25% sibling recurrence risk, carrier testing of parents and at-risk relatives, and discussion of reproductive options. In the reported consanguineous kindred, counseling was provided and prenatal diagnosis on chorionic villus sampling was offered because preimplantation genetic diagnosis was not available. Counseling must also address the fact that heterozygous carriers are typically unaffected, which is what makes this entity's recurrence pattern differ from that of the dominant TNNI3 cardiomyopathies.
Show evidence (2 references)
PMID:38924380 SUPPORT Human Clinical
"Genetic counseling was provided for the family and a prenatal diagnosis of choronic villus was proposed in the absence of pre-implantation genetic diagnosis possibilities."
Documents genetic counseling and prenatal diagnosis as the applied management for recurrence risk in a CMD2A family.
PMID:20301486 SUPPORT Other
"Provide a basic view of genetic risk assessment of at-risk asymptomatic relatives of a proband with DCM to inform cardiac surveillance and allow early detection and treatment of DCM to improve long-term outcome."
The GeneReviews DCM overview frames genetic risk assessment of at-risk asymptomatic relatives as a purpose of the chapter, supporting cascade evaluation as standard practice. PARTIAL on two counts: this is generic DCM guidance rather than CMD2A-specific, and the quote is drawn from the chapter's stated purpose — the only prose in the PubMed record — rather than from a Genetic Counseling section. Evidence source is OTHER because GeneReviews is an expert-curated reference work, not a primary study.
🔬

Diagnosis

3
Echocardiography
First-line and usually diagnostic: left ventricular internal dimensions and ejection fraction establish the dilated, hypocontractile phenotype and detect the accompanying functional mitral regurgitation. In an infant presenting with tachypnea and poor feeding, echocardiography is what converts a presumed respiratory illness into a cardiomyopathy diagnosis.
echocardiography NCIT:C16525 NCI Thesaurus (NCIT)
Show evidence (2 references)
PMID:31073128 SUPPORT Other
"Echocardiography and other imaging techniques are required to assess ventricular dysfunction and adverse myocardial remodelling"
Establishes echocardiography as the required modality for assessing the ventricular dysfunction that defines DCM, of which CMD2A is a genetic form. Evidence source is OTHER because this is a Nature Reviews Disease Primers review.
PMID:38089682 SUPPORT Human Clinical
"Doppler echocardiography showed refractory low ejection fraction, cardiac enlargement, cardiac insufficiency, mild pulmonary hypertension, and mitral and tricuspid insufficiency with mild valve regurgitation."
Shows the echocardiographic findings that establish the diagnosis in a neonate with a TNNI3 variant. PARTIAL because this patient's variant was de novo heterozygous rather than biallelic, so the citation supports the imaging workup rather than the recessive genotype.
Molecular Genetic Testing
Exome or targeted cardiomyopathy-panel sequencing establishes the diagnosis and, critically, its recessive mode. Trio analysis is the informative design: it demonstrates that each unaffected parent carries one allele and that the proband carries two, distinguishing CMD2A from a de novo dominant TNNI3 variant. Copy-number analysis must be included, since a whole-gene deletion can be the second allele and would be missed by sequence analysis alone.
trio exome sequencing NCIT:C101295 NCI Thesaurus (NCIT)
Show evidence (2 references)
PMID:38924380 SUPPORT Human Clinical
"Exome sequencing was performed for the trio (the second deceased infant and her parents). Data analysis following the autosomal dominant and recessive patterns of inheritance was carried out"
Documents trio exome sequencing with explicit dominant-versus-recessive analysis as the diagnostic route to a CMD2A genotype.
PMID:36565796 SUPPORT Human Clinical
"Sanger sequencing and real-time quantitative PCR were used to confirm the variants identified."
Documents the confirmatory workflow including quantitative PCR, the method that detects the whole-gene deletion allele that sequencing alone would miss.
Splicing Functional Assay
A minigene splicing assay is required to interpret candidate synonymous or near-splice TNNI3 variants, which are otherwise easy to dismiss as benign. This is not routine diagnostics but is decisive when standard variant annotation leaves a recessive genotype only half explained.
minigene splicing functional assay NCIT:C15709 NCI Thesaurus (NCIT)
Show evidence (1 reference)
PMID:36565796 SUPPORT In Vitro
"Minigene splicing analyses showed it led to an intron retention (c.24 + 1_24 + 45ins) by intron 2 cryptic splicing."
Demonstrates the assay establishing that a synonymous TNNI3 variant is in fact a loss-of-function allele.
📈

Progression

3
Prenatal and neonatal latency
A cTnI-null fetus develops normally and is born with normal heart and body weight, because slow skeletal troponin I occupies the troponin complex in place of the missing cardiac isoform. This is a true latent phase, not merely a presymptomatic one — the substituting protein is genuinely doing the regulatory job. It is also why prenatal imaging is not expected to identify affected pregnancies, and why families at 25% recurrence risk are counselled toward molecular prenatal diagnosis rather than fetal echocardiography.
Show evidence (1 reference)
PMID:9915769 SUPPORT Model Organism
"Mice lacking cardiac troponin I were born healthy, with normal heart and body weight, because a fetal troponin I isoform (identical to slow skeletal troponin I) compensated for the absence of cardiac troponin I."
Establishes the mechanism of the latent phase. Model organism evidence; the human correlate is that affected infants are described as presenting after birth rather than with prenatal or immediately postnatal cardiac failure.
Decompensation as ssTnI is withdrawn
Loss of the fetal isoform converts a compensated null heart into a troponin I-deficient one, and clinical failure follows. In the mouse this is a sharp event — ssTnI decline from day 15, death on day 18. In children the equivalent window is the neonatal period to the first months of life, with presentation as tachypnea, feeding difficulty, and refractory low ejection fraction.
Show evidence (2 references)
PMID:9915769 SUPPORT Model Organism
"Mice died of acute heart failure on day 18, demonstrating that some form of troponin I is required for normal cardiac function and survival."
Times decompensation to the completion of ssTnI withdrawal.
PMID:36981019 SUPPORT Human Clinical
"biallelic TNNI3 null mutations cause a severe form of neonatal dilated cardiomyopathy"
Places the human decompensation window in the neonatal period.
Refractory heart failure and death or transplantation
Once established, the cardiomyopathy is severe and typically progressive despite medical therapy. Reported outcomes include death within the first year in multiple siblings of one kindred and death shortly after diagnosis in another patient; in the restrictive variant of the recessive series, treatment refractoriness led to transplantation at 28 months. Transplantation is the only definitive option because the underlying lesion is a permanently absent regulatory protein.
Show evidence (2 references)
PMID:38924380 SUPPORT Human Clinical
"Here, we report a family with three deceased offspring at the age of 1 year old."
Documents the lethal natural history in an untransplanted kindred.
PMID:41918167 SUPPORT Human Clinical
"The RCM in this patient was treatment refractory and resulted in a heart transplant at the age of 28 months."
Documents treatment refractoriness and transplantation in the recessive TNNI3 series. PARTIAL because this patient's phenotype was restrictive rather than dilated.
📊

Prevalence

1
Worldwide
Cases In Literature Not yet documented
No population-based prevalence estimate exists for the recessive TNNI3 form of dilated cardiomyopathy. The entity is known from a small number of families, many of them consanguineous, and the literature is still at the case-series-plus-review stage: reports describe the biallelic TNNI3 genotype as a rare cause of neonatal-onset DCM rather than assigning it a population frequency. In the ClinGen curation of 51 DCM genes, TNNI3 sat in the moderate-evidence tier for DCM overall in 2021 and was subsequently upgraded to Strong for both the dominant and the recessive relationship.
Show evidence (2 references)
PMID:36981019 SUPPORT Human Clinical
"the role of TNNI3 null mutations has been more debated due to the paucity and weak characterization of reported cases and the low penetrance of heterozygous genotypes"
Documents that the recessive TNNI3 entity rests on a small number of reported cases, which is why no population prevalence is available. PARTIAL because it characterizes the evidence base rather than measuring occurrence.
PMID:33947203 SUPPORT Human Clinical
"Seven genes (14%; ACTC1, ACTN2, JPH2, NEXN, TNNI3, TPM1, VCL) including 2 additional ontologies were classified as moderate evidence; these genes are likely to emerge as strong or definitive with additional evidence."
Places TNNI3 among the minority (non-definitive at the time of curation) DCM genes, supporting the rarity statement. PARTIAL because it is a gene-evidence tier rather than a prevalence measurement, and it addresses TNNI3-DCM as a whole rather than the recessive subset.
🔀

Differential Diagnoses

3

Conditions with similar clinical presentations that must be differentiated from Dilated Cardiomyopathy 2A:

Recessive TNNI3 restrictive cardiomyopathy
Overlapping Features A biallelic TNNI3 genotype does not guarantee a dilated phenotype: a distal homozygous nonsense allele has been reported to cause severe pediatric restrictive cardiomyopathy with diastolic rather than systolic failure. This is the closest differential within the recessive series itself and is distinguished echocardiographically.
Show evidence (1 reference)
PMID:41918167 SUPPORT Human Clinical
"Dilated cardiomyopathy (DCM) results from systolic dysfunction, while restrictive cardiomyopathy (RCM) is due to diastolic dysfunction."
States the physiological distinction on which this differential turns, in the paper that reports a homozygous TNNI3 nonsense genotype presenting as restrictive rather than dilated cardiomyopathy.
Other genetic and acquired causes of infantile dilated cardiomyopathy
Overlapping Features Neonatal and infantile DCM has many causes besides TNNI3 — other sarcomeric and cytoskeletal genes, inborn errors of metabolism and mitochondrial disease, and acquired myocarditis, most often viral. Roughly half of DCM overall is monogenic, so a genetic diagnosis is not assumed and myocarditis must be excluded before a familial label is applied.
Show evidence (2 references)
PMID:31073128 SUPPORT Other
"Nongenetic forms of DCM can result from different aetiologies, including inflammation of the myocardium due to an infection (mostly viral); exposure to drugs, toxins or allergens; and systemic endocrine or autoimmune diseases."
Enumerates the acquired differential that must be excluded before a familial DCM diagnosis. Evidence source is OTHER because this is a review.
PMID:38924380 SUPPORT Human Clinical
"A monogenic molecular etiology accounts for nearly half of cases."
Quantifies the monogenic fraction of DCM, framing why the non-genetic differential remains substantial.
🧫

Experimental Models

1
Tnni3-null (cardiac troponin I knockout) mouse OTHER
Germline deletion of the cardiac troponin I isoform by gene targeting in murine embryonic stem cells. The reference model for CMD2A, and unusually faithful to it: the mice are born healthy under slow skeletal troponin I cover, ssTnI declines from day 15, and the animals die of acute heart failure on day 18, reproducing the human pattern of a well neonate who decompensates once the isoform switch completes. Isolated ventricular myocytes provide the myofilament-level readouts (sarcomere length, resting tension, calcium sensitivity) that are not obtainable from patients.
Cardiomyocyte CL:0000746 Cell Ontology (CL) Relation: this experimental model uses this cell type This experimental model uses Cardiomyocyte, annotated with cardiac muscle cell (CL:0000746). CL:0000746 is a cell type from the Cell Ontology.
Organism
house mouse NCBITaxon:10090 NCBI Taxonomy (NCBITaxon) Relation: this experimental model is built in this organism This experimental model is built in house mouse, annotated with Mus musculus (NCBITaxon:10090). NCBITaxon:10090 is an organism from the NCBI Taxonomy.
Publication
PMID:9915769
Pathograph links
Perinatal Troponin I Isoform Switch and Loss of ssTnI Compensation The model's central result is the timing of ssTnI withdrawal in a cTnI-null background and the consequent onset of failure.
Show evidence (1 reference)
PMID:9915769 SUPPORT Model Organism
"15 days after birth slow skeletal troponin I expression began a steady decline, giving rise to a troponin I deficiency"
The model's measurement of the ssTnI withdrawal schedule that this pathophysiology node describes.
Thin-Filament Regulatory Failure and Impaired Myofilament Mechanics Isolated ventricular myocytes supply the sarcomere-length, resting-tension, and calcium-sensitivity measurements of troponin I depletion.
Show evidence (1 reference)
PMID:9915769 SUPPORT Model Organism
"Ventricular myocytes isolated from these troponin I-depleted hearts displayed shortened sarcomeres and elevated resting tension measured under relaxing conditions"
The myofilament-mechanics readouts the model contributes to this node.
Show evidence (1 reference)
PMID:9915769 SUPPORT Model Organism
"We deleted the cardiac isoform of troponin I by using gene targeting in murine embryonic stem cells to determine the developmental and physiological effects of the absence of this regulatory protein."
Describes the construction of the model and its purpose, matching the genotype of CMD2A (complete absence of cardiac troponin I).
{ }

Source YAML

click to show 
name: Dilated Cardiomyopathy 2A
creation_date: "2026-08-02T00:00:00Z"
synonyms:
- CMD2A
- DCM2A
- cardiomyopathy, dilated, 2A
- dilated cardiomyopathy type 2A
- TNNI3-related autosomal recessive dilated cardiomyopathy
description: >-
  Dilated cardiomyopathy 2A (CMD2A) is the autosomal recessive, TNNI3-related
  form of familial isolated dilated cardiomyopathy. TNNI3 encodes cardiac
  troponin I (cTnI), the inhibitory subunit of the sarcomeric troponin complex
  that holds the actin-tropomyosin thin filament in its "off" state until
  calcium binding to troponin C releases the inhibition and permits
  cross-bridge cycling. CMD2A is caused by biallelic loss-of-function (mainly
  protein-truncating, and rarely splice-disrupting or whole-gene-deletion)
  TNNI3 genotypes, and it is mechanistically distinct from the far more common
  heterozygous TNNI3 missense disease that produces autosomal dominant
  hypertrophic (CMH7) and restrictive (RCM1) cardiomyopathy. Its most
  characteristic feature is a developmentally timed onset: the fetal and
  neonatal heart expresses slow skeletal troponin I (ssTnI, TNNI1) instead of
  cTnI, so a cTnI-null heart is protected until the perinatal TnI isoform
  switch withdraws that substitute. Affected children are therefore typically
  well at birth and then decompensate in the neonatal period or first months of
  life with severe left ventricular dilation, profoundly reduced ejection
  fraction, and refractory heart failure; one reported consanguineous kindred
  lost three infant siblings, and the natural history without transplantation
  is frequently lethal in the first year or two. Heterozygous carriers, including
  the parents in consanguineous kindreds, are typically unaffected or show only
  low-penetrance disease. ClinGen's Dilated Cardiomyopathy Gene Curation Expert
  Panel classifies the autosomal recessive TNNI3-DCM relationship as Strong,
  separately from its Strong autosomal dominant TNNI3-DCM classification. The
  degree of residual cTnI appears to set the phenotype within the recessive
  allelic series: complete absence gives dilated cardiomyopathy, whereas a more
  distal truncation retaining partial function has been reported to give
  pediatric restrictive cardiomyopathy instead.
category: Genetic
classifications:
  harrisons_chapter:
  - classification_value: CARDIOVASCULAR
  - classification_value: GENETICS_ENVIRONMENT_DISEASE
disease_term:
  preferred_term: dilated cardiomyopathy 2A
  term:
    id: MONDO:0012746
    label: dilated cardiomyopathy 2A
parents:
- Dilated Cardiomyopathy
- Genetic Disorder
prevalence:
- population: Worldwide
  measure_type: CASES_IN_LITERATURE
  prevalence_class: NOT_YET_DOCUMENTED
  notes: >-
    No population-based prevalence estimate exists for the recessive TNNI3 form
    of dilated cardiomyopathy. The entity is known from a small number of
    families, many of them consanguineous, and the literature is still at the
    case-series-plus-review stage: reports describe the biallelic TNNI3
    genotype as a rare cause of neonatal-onset DCM rather than assigning it a
    population frequency. In the ClinGen curation of 51 DCM genes, TNNI3 sat in
    the moderate-evidence tier for DCM overall in 2021 and was subsequently
    upgraded to Strong for both the dominant and the recessive relationship.
  evidence:
  - reference: PMID:36981019
    reference_title: "Homozygous TNNI3 Mutations and Severe Early Onset Dilated Cardiomyopathy: Patient Report and Review of the Literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      the role of TNNI3 null mutations has been more debated due to the paucity
      and weak characterization of reported cases and the low penetrance of
      heterozygous genotypes
    explanation: >-
      Documents that the recessive TNNI3 entity rests on a small number of
      reported cases, which is why no population prevalence is available.
      PARTIAL because it characterizes the evidence base rather than measuring
      occurrence.
  - reference: PMID:33947203
    reference_title: Evidence-Based Assessment of Genes in Dilated Cardiomyopathy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Seven genes (14%; ACTC1, ACTN2, JPH2, NEXN, TNNI3, TPM1, VCL) including 2
      additional ontologies were classified as moderate evidence; these genes are
      likely to emerge as strong or definitive with additional evidence.
    explanation: >-
      Places TNNI3 among the minority (non-definitive at the time of curation)
      DCM genes, supporting the rarity statement. PARTIAL because it is a
      gene-evidence tier rather than a prevalence measurement, and it addresses
      TNNI3-DCM as a whole rather than the recessive subset.
inheritance:
- name: Autosomal Recessive
  description: >-
    CMD2A is transmitted as an autosomal recessive trait: affected individuals
    carry two loss-of-function TNNI3 alleles (homozygous in consanguineous
    families, compound heterozygous otherwise), while heterozygous parents and
    relatives are typically unaffected or show only low-penetrance disease. This
    recessive mode is what distinguishes CMD2A from the dominant TNNI3
    cardiomyopathies, and TNNI3 was the first gene shown to cause dilated
    cardiomyopathy in this manner.
  inheritance_term:
    preferred_term: Autosomal recessive inheritance
    term:
      id: HP:0000007
      label: Autosomal recessive inheritance
  evidence:
  - reference: PMID:15070570
    reference_title: Novel mutation in cardiac troponin I in recessive idiopathic dilated cardiomyopathy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      TNNI3 is the first recessive gene identified for this condition, and we
      suggest that other such genes could be pinpointed by mutation analyses
      designed to identify homozygous mutations.
    explanation: >-
      The founding CMD2A report explicitly establishes TNNI3 as a recessive
      dilated cardiomyopathy gene.
  - reference: CGGV:assertion_b89182f6-1574-48c6-832f-add41ffbaa4c-2025-04-18T160000.000Z
    reference_title: "TNNI3 / dilated cardiomyopathy (Strong)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      TNNI3 | HGNC:11947 | dilated cardiomyopathy | MONDO:0005021 | AR | Strong
    explanation: >-
      ClinGen's Dilated Cardiomyopathy Gene Curation Expert Panel records an
      autosomal recessive TNNI3-DCM gene-disease relationship with Strong
      clinical validity, curated separately from the dominant relationship.
  - reference: PMID:38924380
    reference_title: Homozygous TNNI3 frameshift variant in a consanguineous family with lethal infantile dilated cardiomyopathy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We identified a homozygous frameshift variant in the TNNI3 gene
      (c.204delG; p.(Arg69AlafsTer8)).
    explanation: >-
      Homozygosity for a truncating TNNI3 allele in a consanguineous family with
      three affected infant siblings and unaffected parents — the canonical
      recessive pedigree structure.
mechanistic_hypotheses:
- hypothesis_group_id: tnni3_null_isoform_switch_model
  hypothesis_label: cTnI-null / perinatal TnI isoform-switch model
  status: CANONICAL
  description: >-
    The canonical model holds that biallelic TNNI3 loss-of-function abolishes
    cardiac troponin I, and that the resulting disease is timed by the
    developmental troponin I isoform switch. In fetal and neonatal myocardium
    the slow skeletal isoform (ssTnI, TNNI1) occupies the troponin complex and
    substitutes functionally for cTnI, so a cTnI-null heart develops and is born
    structurally normal. ssTnI is then downregulated on its own developmental
    schedule regardless of whether cTnI is available to replace it, and the
    heart is left globally troponin I-deficient. Thin-filament regulation
    fails — sarcomeres shorten, resting (diastolic) tension rises, and
    myofilament calcium sensitivity under activating conditions falls — giving
    an abrupt, severe, and frequently lethal heart failure in the neonatal
    period or first months of life. The Tnni3-null mouse reproduces exactly this
    time course.
  evidence:
  - reference: PMID:9915769
    reference_title: "Cardiac troponin I gene knockout: a mouse model of myocardial troponin I deficiency."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Mice lacking cardiac troponin I were born healthy, with normal heart and
      body weight, because a fetal troponin I isoform (identical to slow skeletal
      troponin I) compensated for the absence of cardiac troponin I. Compensation
      was only temporary, however, as 15 days after birth slow skeletal troponin
      I expression began a steady decline, giving rise to a troponin I
      deficiency.
    explanation: >-
      Directly demonstrates the isoform-switch timing that is the core of this
      model: normal birth under ssTnI cover, then decompensation when ssTnI is
      withdrawn.
- hypothesis_group_id: tnni3_residual_function_phenotype_model
  hypothesis_label: Residual-cTnI-dose model of dilated versus restrictive phenotype
  status: EMERGING
  description: >-
    An emerging refinement proposes that within the recessive TNNI3 allelic
    series it is the amount of residual cTnI function, not simply the presence of
    biallelic truncation, that determines whether the child develops dilated or
    restrictive cardiomyopathy. Complete absence of cTnI produces the systolic,
    dilated phenotype of CMD2A; a more distal nonsense allele that leaves a
    partially functional (though reduced-abundance) protein has been reported to
    produce severe pediatric restrictive cardiomyopathy instead. If correct, the
    recessive TNNI3 phenotype is a graded function of residual protein rather
    than a binary null state, and the CMD2A/RCM boundary is set by truncation
    position.
  evidence:
  - reference: PMID:41918167
    reference_title: A homozygous variant in cardiac troponin I3, TNNI3, causes severe pediatric restrictive cardiomyopathy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In myocardial biopsies of the patient, TNNI3 protein abundance was
      diminished, suggesting that residual TNNI3 function may underlie RCM, while
      TNNI3 absence causes DCM.
    explanation: >-
      States the residual-function hypothesis explicitly and supplies the
      myocardial-biopsy protein-abundance observation it rests on. Marked
      EMERGING because it currently rests on a single reported patient.
pathophysiology:
- name: Biallelic TNNI3 Loss of Function
  conforms_to: "cardiomyopathy_maladaptive_remodeling#Primary Cardiomyocyte Insult"
  biological_scale: MOLECULAR
  role: trigger
  description: >-
    TNNI3 encodes cardiac troponin I, the inhibitory subunit of the troponin
    complex and one of the three regulatory proteins (with troponin C and
    troponin T) that confer calcium sensitivity on the sarcomeric thin filament.
    CMD2A arises when both TNNI3 alleles are inactivated — most often by
    nonsense or frameshift variants (p.Arg69Alafs*8, p.Arg98*), but also by a
    synonymous variant creating a cryptic splice site with intron retention in
    trans with a whole-gene deletion. The lesion is a true loss of function
    rather than the dominant-negative or altered-function mechanism that
    characterizes the heterozygous TNNI3 missense variants responsible for
    hypertrophic and restrictive cardiomyopathy, which is why the disease is
    recessive and heterozygous carriers are largely spared.
  genes:
  - preferred_term: TNNI3
    term:
      id: hgnc:11947
      label: TNNI3
  molecular_functions:
  - preferred_term: actin binding
    term:
      id: GO:0003779
      label: actin binding
    modifier: DECREASED
  cellular_components:
  - preferred_term: troponin complex
    term:
      id: GO:0005861
      label: troponin complex
    modifier: ABNORMAL
  cell_types:
  - preferred_term: Cardiomyocyte
    term:
      id: CL:0000746
      label: cardiac muscle cell
  locations:
  - preferred_term: Myocardium
    term:
      id: UBERON:0002349
      label: myocardium
  biological_processes:
  - preferred_term: Regulation of cardiac muscle contraction
    term:
      id: GO:0055117
      label: regulation of cardiac muscle contraction
    modifier: ABNORMAL
  evidence:
  - reference: PMID:26526134
    reference_title: "TNNI1, TNNI2 and TNNI3: Evolution, regulation, and protein structure-function relationships."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Troponin I (TnI) is the inhibitory subunit of the troponin complex in the
      sarcomeric thin filament of striated muscle and plays a central role in the
      calcium regulation of contraction and relaxation.
    explanation: >-
      Establishes the normal function of troponin I — thin-filament inhibition
      and calcium regulation of contraction and relaxation — that biallelic
      TNNI3 loss abolishes. Evidence source is OTHER because this is a
      structure-function review.
  - reference: PMID:36981019
    reference_title: "Homozygous TNNI3 Mutations and Severe Early Onset Dilated Cardiomyopathy: Patient Report and Review of the Literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In recent years, however, an increasing amount of evidence has validated
      the hypothesis that biallelic TNNI3 null mutations cause a severe form of
      neonatal dilated cardiomyopathy.
    explanation: >-
      States the causal claim of this node: biallelic TNNI3 null genotypes, not
      heterozygous missense change, are what produce this disease.
  - reference: PMID:15070570
    reference_title: Novel mutation in cardiac troponin I in recessive idiopathic dilated cardiomyopathy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We identified a novel TNNI3 mutation in a family with recessive disease.
    explanation: >-
      The founding human observation of a recessive TNNI3 genotype segregating
      in a family. Deliberately trimmed to the clinical sentence: the paper's
      accompanying functional-studies result is in vitro and is modeled as a
      separate IN_VITRO evidence item on the thin-filament node, so that one
      item is not tagged with two source types.
  downstream:
  - target: Perinatal Troponin I Isoform Switch and Loss of ssTnI Compensation
    causal_link_type: DIRECT
    hypothesis_groups:
    - tnni3_null_isoform_switch_model
    description: >-
      A cTnI-null heart is only unmasked once the fetal isoform that has been
      standing in for cTnI is withdrawn.

- name: Perinatal Troponin I Isoform Switch and Loss of ssTnI Compensation
  biological_scale: CELLULAR
  role: intermediate
  description: >-
    The heart expresses two troponin I isoforms under developmental control: the
    slow skeletal isoform (ssTnI, TNNI1) in fetal and early postnatal
    myocardium, replaced by cardiac troponin I (cTnI, TNNI3) as the heart
    matures. In a cTnI-null heart, ssTnI initially occupies the troponin complex
    and supports normal development, normal birth weight, and normal cardiac
    structure at birth. Critically, ssTnI downregulation proceeds on its own
    developmental schedule and is not held back by the absence of cTnI, so the
    myocardium passes from ssTnI-supported regulation to no troponin I at all.
    This node explains the entity's most distinctive clinical feature — a well
    child who decompensates abruptly in the neonatal period or first months —
    and is why CMD2A is a disease of infancy rather than of adulthood like most
    sarcomeric cardiomyopathy.
  cell_types:
  - preferred_term: Cardiomyocyte
    term:
      id: CL:0000746
      label: cardiac muscle cell
  biological_processes:
  - preferred_term: Regulation of striated muscle contraction
    term:
      id: GO:0006942
      label: regulation of striated muscle contraction
    modifier: ABSENT
  evidence:
  - reference: PMID:9915769
    reference_title: "Cardiac troponin I gene knockout: a mouse model of myocardial troponin I deficiency."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      The results show that (1) developmental downregulation of slow skeletal
      troponin I occurs even in the absence of cardiac troponin I and (2) the
      resultant troponin I depletion alters specific mechanical properties of
      myocardium and can lead to a lethal form of acute heart failure.
    explanation: >-
      Establishes both halves of this node: ssTnI is withdrawn regardless of
      cTnI status, and the resulting global troponin I depletion is what causes
      lethal heart failure. Model organism evidence; the corresponding human
      claim is the neonatal-onset timing documented in the patient reports.
  - reference: PMID:26526134
    reference_title: "TNNI1, TNNI2 and TNNI3: Evolution, regulation, and protein structure-function relationships."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Vertebrate TnI has evolved into three isoforms encoded by three homologous
      genes: TNNI1 for slow skeletal muscle TnI, TNNI2 for fast skeletal muscle
      TnI and TNNI3 for cardiac TnI, which are expressed under muscle
      type-specific and developmental regulations.
    explanation: >-
      Documents the developmentally regulated TnI isoform system on which the
      ssTnI-compensation mechanism depends. Evidence source is OTHER because
      this is a review.
  downstream:
  - target: Thin-Filament Regulatory Failure and Impaired Myofilament Mechanics
    causal_link_type: DIRECT
    hypothesis_groups:
    - tnni3_null_isoform_switch_model

- name: Thin-Filament Regulatory Failure and Impaired Myofilament Mechanics
  biological_scale: CELLULAR
  role: amplifier
  description: >-
    Without any troponin I, the thin filament loses the inhibitory element that
    normally keeps tropomyosin over the myosin-binding sites at low calcium and
    that transduces calcium binding at troponin C into cooperative filament
    activation. The measured consequence in troponin I-depleted ventricular
    myocytes is a combined systolic and diastolic defect: sarcomeres are
    shortened and resting tension is elevated under relaxing conditions, while
    myofilament calcium sensitivity is reduced under activating conditions.
    Contraction is therefore both incompletely switched off between beats and
    inefficiently switched on during systole, degrading net pump performance.
    In the recessive human allelic series the severity of this regulatory
    failure appears to track residual cTnI abundance.
  cell_types:
  - preferred_term: Cardiac ventricular myocyte
    term:
      id: CL:0000746
      label: cardiac muscle cell
  biological_processes:
  - preferred_term: Cardiac muscle contraction
    term:
      id: GO:0060048
      label: cardiac muscle contraction
    modifier: DECREASED
  - preferred_term: Regulation of cardiac muscle cell contraction
    term:
      id: GO:0086004
      label: regulation of cardiac muscle cell contraction
    modifier: ABNORMAL
  evidence:
  - reference: PMID:9915769
    reference_title: "Cardiac troponin I gene knockout: a mouse model of myocardial troponin I deficiency."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Ventricular myocytes isolated from these troponin I-depleted hearts
      displayed shortened sarcomeres and elevated resting tension measured under
      relaxing conditions and had a reduced myofilament Ca sensitivity under
      activating conditions.
    explanation: >-
      Supplies the specific myofilament mechanics of troponin I depletion —
      elevated diastolic tension plus reduced calcium sensitivity — that this
      node asserts.
  - reference: PMID:15070570
    reference_title: Novel mutation in cardiac troponin I in recessive idiopathic dilated cardiomyopathy.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Functional studies showed impairment of troponin interactions that could
      lead to diminished myocardial contractility.
    explanation: >-
      Human-variant functional data linking the recessive TNNI3 lesion to
      impaired troponin interactions and reduced contractility. Classified
      IN_VITRO because the functional studies were biochemical assays of
      troponin interaction rather than patient observations.
  downstream:
  - target: Left Ventricular Dilation and Systolic Failure
    causal_link_type: DIRECT
    hypothesis_groups:
    - tnni3_null_isoform_switch_model

- name: Left Ventricular Dilation and Systolic Failure
  conforms_to: "cardiomyopathy_maladaptive_remodeling#Progressive Contractile Dysfunction"
  biological_scale: ORGANISM
  role: consequence
  description: >-
    The failing myofilament produces the defining organ-level phenotype:
    progressive left ventricular chamber enlargement with severely depressed
    ejection fraction, functional mitral regurgitation from annular dilation,
    and congestive heart failure. Reported infants have presented with left
    ventricular ejection fractions as low as 10%, and the resulting circulatory
    failure is what kills — one reported kindred lost three siblings in the
    first year of life. Because the primary lesion is a permanent absence of a
    structural regulatory protein rather than a modifiable stress, this node
    does not remit; neurohormonal therapy slows it but transplantation is the
    only definitive intervention.
  cell_types:
  - preferred_term: Cardiomyocyte
    term:
      id: CL:0000746
      label: cardiac muscle cell
  locations:
  - preferred_term: Left ventricle
    term:
      id: UBERON:0002084
      label: heart left ventricle
  biological_processes:
  - preferred_term: Cardiac muscle contraction
    term:
      id: GO:0060048
      label: cardiac muscle contraction
    modifier: DECREASED
  evidence:
  - reference: PMID:38924380
    reference_title: Homozygous TNNI3 frameshift variant in a consanguineous family with lethal infantile dilated cardiomyopathy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The second infant presented a DCM phenotype with a severely reduced Left
      Ventricular Ejection Fraction (LVEF) of 10%.
    explanation: >-
      Quantifies the depth of systolic failure produced by a biallelic
      truncating TNNI3 genotype.
  - reference: PMID:36565796
    reference_title: Identification of a novel TNNI3 synonymous variant causing intron retention in autosomal recessive dilated cardiomyopathy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The one-year-old girl presented severe left ventricular enlargement and
      significantly reduced left ventricular systolic function and she died of
      respiratory and heart failure soon after her diagnosis.
    explanation: >-
      Documents the chamber dilation plus systolic dysfunction combination and
      its lethal outcome in a compound heterozygous TNNI3 patient.
phenotypes:
- category: Cardiovascular
  name: Dilated cardiomyopathy
  description: >-
    The defining phenotype: a dilated, poorly contracting left ventricle in the
    absence of abnormal loading conditions or coronary disease. In CMD2A it is
    typically severe and of neonatal or early infantile onset — the signature
    timing explained by the perinatal troponin I isoform switch, which leaves
    the ssTnI-supported fetal heart normal at birth and unmasks the cTnI-null
    state only as ssTnI is withdrawn.
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Dilated cardiomyopathy
    term:
      id: HP:0001644
      label: Dilated cardiomyopathy
    onset:
      onset_category: NEONATAL
      notes: >-
        Characteristically neonatal, but the reported window extends through the
        first year of life; onset is not congenital, since affected infants are
        structurally normal at birth.
  evidence:
  - reference: PMID:36981019
    reference_title: "Homozygous TNNI3 Mutations and Severe Early Onset Dilated Cardiomyopathy: Patient Report and Review of the Literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      biallelic TNNI3 null mutations cause a severe form of neonatal dilated
      cardiomyopathy
    explanation: >-
      Dilated cardiomyopathy is the obligate phenotype of the biallelic TNNI3
      genotype and is characterized as neonatal in onset, supporting both the
      VERY_FREQUENT band and the NEONATAL onset category.
  - reference: PMID:38924380
    reference_title: Homozygous TNNI3 frameshift variant in a consanguineous family with lethal infantile dilated cardiomyopathy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Here, we report a family with three deceased offspring at the age of 1 year
      old.
    explanation: >-
      Documents infantile presentation and death in three affected siblings,
      showing that the onset window extends beyond the strictly neonatal period.
- category: Cardiovascular
  name: Left ventricular dilatation
  description: >-
    Enlargement of the left ventricular cavity, the structural half of the
    dilated phenotype and the finding that establishes it on echocardiography.
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Left ventricular dilatation
    term:
      id: HP:4000141
      label: Left ventricular dilatation
  evidence:
  - reference: PMID:36565796
    reference_title: Identification of a novel TNNI3 synonymous variant causing intron retention in autosomal recessive dilated cardiomyopathy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The one-year-old girl presented severe left ventricular enlargement
    explanation: >-
      Direct observation of left ventricular cavity enlargement in a patient
      with biallelic TNNI3 loss of function.
- category: Cardiovascular
  name: Reduced left ventricular ejection fraction
  description: >-
    Severely depressed systolic function; reported infants have had ejection
    fractions of 10% to 30%, and refractory low ejection fraction is
    characteristic.
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Reduced left ventricular ejection fraction
    term:
      id: HP:0012664
      label: Reduced left ventricular ejection fraction
    severity: SEVERE
  evidence:
  - reference: PMID:38924380
    reference_title: Homozygous TNNI3 frameshift variant in a consanguineous family with lethal infantile dilated cardiomyopathy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Similarly, the third infant showed a severe DCM phenotype with LVEF of 30%
      as well, in addition to eccentric mitral insufficiency.
    explanation: >-
      Quantifies severely reduced ejection fraction in a second affected sibling
      of the same consanguineous kindred.
- category: Cardiovascular
  name: Left ventricular systolic dysfunction
  description: >-
    Impaired systolic performance of the left ventricle, the functional
    counterpart of the chamber dilation.
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Left ventricular systolic dysfunction
    term:
      id: HP:0025169
      label: Left ventricular systolic dysfunction
  evidence:
  - reference: PMID:36565796
    reference_title: Identification of a novel TNNI3 synonymous variant causing intron retention in autosomal recessive dilated cardiomyopathy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      significantly reduced left ventricular systolic function
    explanation: >-
      Direct observation of systolic dysfunction in a patient with biallelic
      TNNI3 loss of function.
- category: Cardiovascular
  name: Congestive heart failure
  description: >-
    Clinical heart failure is the presenting syndrome and the usual cause of
    death; it is frequently refractory to medical therapy in this entity.
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Congestive heart failure
    term:
      id: HP:0001635
      label: Congestive heart failure
    onset:
      onset_category: INFANTILE
  evidence:
  - reference: PMID:36565796
    reference_title: Identification of a novel TNNI3 synonymous variant causing intron retention in autosomal recessive dilated cardiomyopathy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      she died of respiratory and heart failure soon after her diagnosis
    explanation: >-
      Heart failure as the terminal event in a one-year-old patient with
      biallelic TNNI3 loss of function, supporting both the phenotype and its
      infantile onset.
- category: Cardiovascular
  name: Mitral regurgitation
  description: >-
    Functional mitral incompetence from mitral annular dilation as the left
    ventricle enlarges; reported as eccentric mitral insufficiency in an
    affected infant.
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Mitral regurgitation
    term:
      id: HP:0001653
      label: Mitral regurgitation
  evidence:
  - reference: PMID:38924380
    reference_title: Homozygous TNNI3 frameshift variant in a consanguineous family with lethal infantile dilated cardiomyopathy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      in addition to eccentric mitral insufficiency
    explanation: >-
      Documents mitral regurgitation accompanying the dilated phenotype.
      OCCASIONAL rather than a higher band because it is reported in one of the
      described siblings rather than as a consistent feature.
- category: Respiratory
  name: Respiratory distress from pulmonary congestion
  description: >-
    Tachypnea and respiratory compromise from pulmonary venous congestion, which
    is one reason CMD2A can be first suspected as a respiratory illness. The
    OCCASIONAL band reflects how often respiratory features are explicitly
    documented in the small published CMD2A series, not a claim that pulmonary
    congestion is uncommon in decompensated infantile heart failure.
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Tachypnea
    term:
      id: HP:0002789
      label: Tachypnea
  evidence:
  - reference: PMID:36565796
    reference_title: Identification of a novel TNNI3 synonymous variant causing intron retention in autosomal recessive dilated cardiomyopathy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      she died of respiratory and heart failure soon after her diagnosis
    explanation: >-
      Documents respiratory failure accompanying the cardiac failure in a
      biallelic TNNI3 patient. PARTIAL because the quote establishes respiratory
      compromise rather than tachypnea specifically.
- category: Cardiovascular
  name: Sudden cardiac death
  description: >-
    Sudden death is a recognized outcome of childhood cardiomyopathy generally
    and is named as an outcome of DCM2A. It is a less prominent mode of death in
    this entity than progressive pump failure.
  phenotype_term:
    preferred_term: Sudden cardiac death
    term:
      id: HP:0001645
      label: Sudden cardiac death
  evidence:
  - reference: PMID:36565796
    reference_title: Identification of a novel TNNI3 synonymous variant causing intron retention in autosomal recessive dilated cardiomyopathy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Dilated cardiomyopathy type 2A (DCM2A, MIM: #611880) is a rare autosomal
      recessive heart disease leading to heart failure and sudden cardiac death.
    explanation: >-
      Names sudden cardiac death as an outcome of DCM2A specifically. Frequency
      is deliberately omitted — no source quantifies the arrhythmic death rate in
      this entity.
  - reference: PMID:26022819
    reference_title: "Sudden death in childhood cardiomyopathy: results from a long-term national population-based study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The cumulative incidence of SCD at 15 years was 5% for dilated
      cardiomyopathy (DCM), 6% for hypertrophic cardiomyopathy (HCM), 12% for
      restrictive cardiomyopathy, and 23% for left ventricular (LV) noncompaction.
    explanation: >-
      Supplies the background sudden-death risk for childhood dilated
      cardiomyopathy as a class. PARTIAL because the cohort is all childhood DCM,
      not the TNNI3 recessive subset.
genetic:
- name: TNNI3 Biallelic Loss-of-Function Variants
  association: Biallelic Loss-of-Function Variants
  relationship_type: CAUSATIVE
  gene_term:
    preferred_term: TNNI3
    term:
      id: hgnc:11947
      label: TNNI3
  inheritance:
  - name: Autosomal Recessive
    inheritance_term:
      preferred_term: Autosomal recessive inheritance
      term:
        id: HP:0000007
        label: Autosomal recessive inheritance
    evidence:
    - reference: CGGV:assertion_b89182f6-1574-48c6-832f-add41ffbaa4c-2025-04-18T160000.000Z
      reference_title: "TNNI3 / dilated cardiomyopathy (Strong)"
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        TNNI3 | HGNC:11947 | dilated cardiomyopathy | MONDO:0005021 | AR | Strong
      explanation: >-
        ClinGen records AR as the mode of inheritance for this TNNI3-DCM
        gene-disease relationship.
  features: >-
    CMD2A genotypes are biallelic and loss-of-function. Most reported alleles are
    protein-truncating (nonsense or frameshift), and the same alleles recur
    across unrelated families — p.Arg69Alafs*8 in particular. Non-truncating
    routes to the null state also exist: a synonymous exon 2 variant
    (c.24G>A, p.Ala8Ala) that creates a cryptic splice donor and causes intron 2
    retention was found in trans with a whole-gene deletion. Alleles reported in
    the homozygous state in affected children have also been seen in
    heterozygous unaffected carriers, consistent with a recessive mechanism and
    with the low penetrance of the heterozygous state. The recessive
    loss-of-function series is mechanistically separate from the heterozygous
    TNNI3 missense variants that cause dominant hypertrophic (CMH7) and
    restrictive (RCM1) cardiomyopathy, so a TNNI3 variant list cannot be
    interpreted without its zygosity and variant class.
  variants:
  - name: TNNI3 p.Arg69Alafs*8 (c.204delG)
    description: >-
      Recurrent frameshift allele. Reported homozygous in a consanguineous
      Tunisian family with three infants who died at about one year of age, and
      independently in the review series of biallelic TNNI3 loss-of-function
      patients. Classified pathogenic by ACMG criteria.
    gene:
      preferred_term: TNNI3
      term:
        id: hgnc:11947
        label: TNNI3
    evidence:
    - reference: PMID:38924380
      reference_title: Homozygous TNNI3 frameshift variant in a consanguineous family with lethal infantile dilated cardiomyopathy.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        This variant has been recently reported in the ClinVar database in
        association with cardiac phenotypes as pathogenic or likely pathogenic
        and classified as pathogenic according to ACMG.
      explanation: >-
        Records the pathogenicity classification of the recurrent
        p.Arg69Alafs*8 allele.
  - name: TNNI3 p.Arg98*
    description: >-
      Nonsense allele reported in the homozygous state in a patient with
      early-onset dilated cardiomyopathy, having previously been documented only
      in heterozygous patients and apparently healthy carriers — direct evidence
      that the heterozygous state is not equivalent to the biallelic one.
    gene:
      preferred_term: TNNI3
      term:
        id: hgnc:11947
        label: TNNI3
    evidence:
    - reference: PMID:36981019
      reference_title: "Homozygous TNNI3 Mutations and Severe Early Onset Dilated Cardiomyopathy: Patient Report and Review of the Literature."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        homozygosity for the p.Arg98* TNNI3 variant, which had thus far been
        documented only in heterozygous patients and apparently healthy carriers
      explanation: >-
        Establishes both the homozygous disease genotype and the prior
        observation of the same allele in unaffected heterozygotes.
  - name: TNNI3 c.24G>A (p.Ala8Ala)
    description: >-
      Synonymous exon 2 variant that nonetheless abolishes function by creating a
      cryptic intron 2 splice donor, producing intron retention; found in trans
      with a deletion of the entire gene in a Chinese infant with severe dilated
      cardiomyopathy. Demonstrated by minigene splicing assay.
    gene:
      preferred_term: TNNI3
      term:
        id: hgnc:11947
        label: TNNI3
    evidence:
    - reference: PMID:36565796
      reference_title: Identification of a novel TNNI3 synonymous variant causing intron retention in autosomal recessive dilated cardiomyopathy.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: >-
        Minigene splicing analyses showed it led to an intron retention (c.24 +
        1_24 + 45ins) by intron 2 cryptic splicing.
      explanation: >-
        Functional demonstration that this synonymous allele is
        loss-of-function via cryptic splicing.
  - name: TNNI3 p.Arg136* (c.406C>T)
    description: >-
      More distal nonsense allele reported homozygous in a 2-year-old with severe
      pediatric restrictive rather than dilated cardiomyopathy, with diminished
      but detectable TNNI3 protein in myocardial biopsy. Included here as the
      boundary case of the recessive series that motivates the residual-function
      model.
    gene:
      preferred_term: TNNI3
      term:
        id: hgnc:11947
        label: TNNI3
    evidence:
    - reference: PMID:41918167
      reference_title: A homozygous variant in cardiac troponin I3, TNNI3, causes severe pediatric restrictive cardiomyopathy.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        a homozygous TNNI3 nonsense variant, c.406C>T (p.Arg136
      explanation: >-
        Identifies the distal nonsense allele and its homozygous state in the
        reported restrictive-phenotype patient. The snippet stops before the
        terminator glyph, which the source renders with a non-ASCII asterisk.
  evidence:
  - reference: CGGV:assertion_b89182f6-1574-48c6-832f-add41ffbaa4c-2025-04-18T160000.000Z
    reference_title: "TNNI3 / dilated cardiomyopathy (Strong)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      TNNI3 | HGNC:11947 | dilated cardiomyopathy | MONDO:0005021 | AR | Strong
    explanation: >-
      ClinGen's Dilated Cardiomyopathy Gene Curation Expert Panel classifies the
      autosomal recessive TNNI3-DCM gene-disease relationship as Strong under
      SOP10.
  - reference: PMID:36981019
    reference_title: "Homozygous TNNI3 Mutations and Severe Early Onset Dilated Cardiomyopathy: Patient Report and Review of the Literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      two unrelated patients afflicted with early onset dilated cardiomyopathy,
      due to homozygosity for the p.Arg98* TNNI3 variant, which had thus far been
      documented only in heterozygous patients and apparently healthy carriers,
      and the recurrent p.Arg69Alafs*8 variant, respectively
    explanation: >-
      Names both recurrent truncating alleles and records that p.Arg98* occurs in
      healthy heterozygous carriers — the key zygosity argument for a recessive
      mechanism.
  - reference: PMID:36565796
    reference_title: Identification of a novel TNNI3 synonymous variant causing intron retention in autosomal recessive dilated cardiomyopathy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      a novel c.24G＞A (p.Ala8Ala) (NM_000363.4) in exon 2 and a deletion of
      entire gene
    explanation: >-
      Documents the compound heterozygous synonymous-plus-deletion genotype, and
      shows that a synonymous variant can be a CMD2A allele.
  - reference: PMID:41918167
    reference_title: A homozygous variant in cardiac troponin I3, TNNI3, causes severe pediatric restrictive cardiomyopathy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In children, bi-allelic truncating TNNI3 variants have typically been
      associated with DCM, and heterozygous missense TNNI3 variants are
      associated with RCM.
    explanation: >-
      States the zygosity-and-variant-class rule that separates the recessive
      CMD2A series from the dominant TNNI3 cardiomyopathies.
diagnosis:
- name: Echocardiography
  description: >-
    First-line and usually diagnostic: left ventricular internal dimensions and
    ejection fraction establish the dilated, hypocontractile phenotype and detect
    the accompanying functional mitral regurgitation. In an infant presenting
    with tachypnea and poor feeding, echocardiography is what converts a
    presumed respiratory illness into a cardiomyopathy diagnosis.
  diagnosis_term:
    preferred_term: echocardiography
    term:
      id: NCIT:C16525
      label: Echocardiography Test
  evidence:
  - reference: PMID:31073128
    reference_title: Dilated cardiomyopathy.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Echocardiography and other imaging techniques are required to assess
      ventricular dysfunction and adverse myocardial remodelling
    explanation: >-
      Establishes echocardiography as the required modality for assessing the
      ventricular dysfunction that defines DCM, of which CMD2A is a genetic form.
      Evidence source is OTHER because this is a Nature Reviews Disease Primers
      review.
  - reference: PMID:38089682
    reference_title: "Case Report: Mutation in TNNI3(c. 544G>A): a novel likely pathogenic mechanism of neonatal dilated cardiomyopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Doppler echocardiography showed refractory low ejection fraction, cardiac
      enlargement, cardiac insufficiency, mild pulmonary hypertension, and mitral
      and tricuspid insufficiency with mild valve regurgitation.
    explanation: >-
      Shows the echocardiographic findings that establish the diagnosis in a
      neonate with a TNNI3 variant. PARTIAL because this patient's variant was
      de novo heterozygous rather than biallelic, so the citation supports the
      imaging workup rather than the recessive genotype.
- name: Molecular Genetic Testing
  description: >-
    Exome or targeted cardiomyopathy-panel sequencing establishes the diagnosis
    and, critically, its recessive mode. Trio analysis is the informative design:
    it demonstrates that each unaffected parent carries one allele and that the
    proband carries two, distinguishing CMD2A from a de novo dominant TNNI3
    variant. Copy-number analysis must be included, since a whole-gene deletion
    can be the second allele and would be missed by sequence analysis alone.
  diagnosis_term:
    preferred_term: trio exome sequencing
    term:
      id: NCIT:C101295
      label: Whole Exome Sequencing
  evidence:
  - reference: PMID:38924380
    reference_title: Homozygous TNNI3 frameshift variant in a consanguineous family with lethal infantile dilated cardiomyopathy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Exome sequencing was performed for the trio (the second deceased infant
      and her parents). Data analysis following the autosomal dominant and
      recessive patterns of inheritance was carried out
    explanation: >-
      Documents trio exome sequencing with explicit dominant-versus-recessive
      analysis as the diagnostic route to a CMD2A genotype.
  - reference: PMID:36565796
    reference_title: Identification of a novel TNNI3 synonymous variant causing intron retention in autosomal recessive dilated cardiomyopathy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Sanger sequencing and real-time quantitative PCR were used to confirm the
      variants identified.
    explanation: >-
      Documents the confirmatory workflow including quantitative PCR, the method
      that detects the whole-gene deletion allele that sequencing alone would
      miss.
- name: Splicing Functional Assay
  description: >-
    A minigene splicing assay is required to interpret candidate synonymous or
    near-splice TNNI3 variants, which are otherwise easy to dismiss as benign.
    This is not routine diagnostics but is decisive when standard variant
    annotation leaves a recessive genotype only half explained.
  diagnosis_term:
    preferred_term: minigene splicing functional assay
    term:
      id: NCIT:C15709
      label: Genetic Testing
  evidence:
  - reference: PMID:36565796
    reference_title: Identification of a novel TNNI3 synonymous variant causing intron retention in autosomal recessive dilated cardiomyopathy.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Minigene splicing analyses showed it led to an intron retention (c.24 +
      1_24 + 45ins) by intron 2 cryptic splicing.
    explanation: >-
      Demonstrates the assay establishing that a synonymous TNNI3 variant is in
      fact a loss-of-function allele.
differential_diagnoses:
- name: TNNI3-related hypertrophic and restrictive cardiomyopathy (CMH7, RCM1)
  description: >-
    The same gene, but the dominant, heterozygous, missense form. These are the
    long-established and far more common TNNI3 diseases; distinguishing them from
    CMD2A is a matter of zygosity, variant class, and phenotype rather than gene
    identity. A heterozygous TNNI3 missense variant in a child with a dilated
    ventricle should not be reported as CMD2A.
  evidence:
  - reference: PMID:36981019
    reference_title: "Homozygous TNNI3 Mutations and Severe Early Onset Dilated Cardiomyopathy: Patient Report and Review of the Literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      While heterozygous TNNI3 missense mutations have long been associated with
      autosomal dominant hypertrophic and restrictive cardiomyopathies, the role
      of TNNI3 null mutations has been more debated
    explanation: >-
      States the contrast between the dominant missense TNNI3 diseases and the
      recessive null disease curated here.
- name: Recessive TNNI3 restrictive cardiomyopathy
  description: >-
    A biallelic TNNI3 genotype does not guarantee a dilated phenotype: a distal
    homozygous nonsense allele has been reported to cause severe pediatric
    restrictive cardiomyopathy with diastolic rather than systolic failure. This
    is the closest differential within the recessive series itself and is
    distinguished echocardiographically.
  evidence:
  - reference: PMID:41918167
    reference_title: A homozygous variant in cardiac troponin I3, TNNI3, causes severe pediatric restrictive cardiomyopathy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Dilated cardiomyopathy (DCM) results from systolic dysfunction, while
      restrictive cardiomyopathy (RCM) is due to diastolic dysfunction.
    explanation: >-
      States the physiological distinction on which this differential turns, in
      the paper that reports a homozygous TNNI3 nonsense genotype presenting as
      restrictive rather than dilated cardiomyopathy.
- name: Other genetic and acquired causes of infantile dilated cardiomyopathy
  description: >-
    Neonatal and infantile DCM has many causes besides TNNI3 — other sarcomeric
    and cytoskeletal genes, inborn errors of metabolism and mitochondrial
    disease, and acquired myocarditis, most often viral. Roughly half of DCM
    overall is monogenic, so a genetic diagnosis is not assumed and myocarditis
    must be excluded before a familial label is applied.
  evidence:
  - reference: PMID:31073128
    reference_title: Dilated cardiomyopathy.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Nongenetic forms of DCM can result from different aetiologies, including
      inflammation of the myocardium due to an infection (mostly viral); exposure
      to drugs, toxins or allergens; and systemic endocrine or autoimmune
      diseases.
    explanation: >-
      Enumerates the acquired differential that must be excluded before a
      familial DCM diagnosis. Evidence source is OTHER because this is a review.
  - reference: PMID:38924380
    reference_title: Homozygous TNNI3 frameshift variant in a consanguineous family with lethal infantile dilated cardiomyopathy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      A monogenic molecular etiology accounts for nearly half of cases.
    explanation: >-
      Quantifies the monogenic fraction of DCM, framing why the non-genetic
      differential remains substantial.
progression:
- phase: Prenatal and neonatal latency
  notes: >-
    A cTnI-null fetus develops normally and is born with normal heart and body
    weight, because slow skeletal troponin I occupies the troponin complex in
    place of the missing cardiac isoform. This is a true latent phase, not merely
    a presymptomatic one — the substituting protein is genuinely doing the
    regulatory job. It is also why prenatal imaging is not expected to identify
    affected pregnancies, and why families at 25% recurrence risk are counselled
    toward molecular prenatal diagnosis rather than fetal echocardiography.
  evidence:
  - reference: PMID:9915769
    reference_title: "Cardiac troponin I gene knockout: a mouse model of myocardial troponin I deficiency."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Mice lacking cardiac troponin I were born healthy, with normal heart and
      body weight, because a fetal troponin I isoform (identical to slow skeletal
      troponin I) compensated for the absence of cardiac troponin I.
    explanation: >-
      Establishes the mechanism of the latent phase. Model organism evidence; the
      human correlate is that affected infants are described as presenting after
      birth rather than with prenatal or immediately postnatal cardiac failure.
- phase: Decompensation as ssTnI is withdrawn
  notes: >-
    Loss of the fetal isoform converts a compensated null heart into a troponin
    I-deficient one, and clinical failure follows. In the mouse this is a sharp
    event — ssTnI decline from day 15, death on day 18. In children the
    equivalent window is the neonatal period to the first months of life, with
    presentation as tachypnea, feeding difficulty, and refractory low ejection
    fraction.
  evidence:
  - reference: PMID:9915769
    reference_title: "Cardiac troponin I gene knockout: a mouse model of myocardial troponin I deficiency."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Mice died of acute heart failure on day 18, demonstrating that some form of
      troponin I is required for normal cardiac function and survival.
    explanation: >-
      Times decompensation to the completion of ssTnI withdrawal.
  - reference: PMID:36981019
    reference_title: "Homozygous TNNI3 Mutations and Severe Early Onset Dilated Cardiomyopathy: Patient Report and Review of the Literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      biallelic TNNI3 null mutations cause a severe form of neonatal dilated
      cardiomyopathy
    explanation: >-
      Places the human decompensation window in the neonatal period.
- phase: Refractory heart failure and death or transplantation
  notes: >-
    Once established, the cardiomyopathy is severe and typically progressive
    despite medical therapy. Reported outcomes include death within the first
    year in multiple siblings of one kindred and death shortly after diagnosis in
    another patient; in the restrictive variant of the recessive series, treatment
    refractoriness led to transplantation at 28 months. Transplantation is the
    only definitive option because the underlying lesion is a permanently absent
    regulatory protein.
  evidence:
  - reference: PMID:38924380
    reference_title: Homozygous TNNI3 frameshift variant in a consanguineous family with lethal infantile dilated cardiomyopathy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Here, we report a family with three deceased offspring at the age of 1 year
      old.
    explanation: >-
      Documents the lethal natural history in an untransplanted kindred.
  - reference: PMID:41918167
    reference_title: A homozygous variant in cardiac troponin I3, TNNI3, causes severe pediatric restrictive cardiomyopathy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The RCM in this patient was treatment refractory and resulted in a heart
      transplant at the age of 28 months.
    explanation: >-
      Documents treatment refractoriness and transplantation in the recessive
      TNNI3 series. PARTIAL because this patient's phenotype was restrictive
      rather than dilated.
treatments:
- name: Guideline-Directed Heart Failure Pharmacotherapy
  description: >-
    Standard anti-remodeling heart-failure therapy — renin-angiotensin system
    blockade, a beta-blocker, and a mineralocorticoid receptor antagonist,
    dosed for age — targeting the neurohormonal amplifier between the
    myofilament lesion and adverse ventricular remodeling. There is no
    TNNI3-specific or troponin-replacing therapy, so management is the generic
    dilated-cardiomyopathy regimen, and in this entity it is frequently
    insufficient: reported infants have had refractory low ejection fraction
    despite treatment.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: ACE inhibitor
      term:
        id: NCIT:C247
        label: ACE Inhibitor
    - preferred_term: beta-blocker
      term:
        id: NCIT:C29576
        label: Beta-Adrenergic Antagonist
    - preferred_term: mineralocorticoid receptor antagonist (spironolactone as the class exemplar)
      term:
        id: NCIT:C840
        label: Spironolactone
  target_mechanisms:
  - target: Left Ventricular Dilation and Systolic Failure
    treatment_effect: INHIBITS
    description: >-
      Neurohormonal blockade slows adverse remodeling downstream of the
      myofilament defect; it does not address the absent troponin I.
  evidence:
  - reference: PMID:31073128
    reference_title: Dilated cardiomyopathy.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      As DCM eventually leads to impaired contractility, standard approaches to
      prevent or treat heart failure are the first-line treatment for patients
      with DCM.
    explanation: >-
      Establishes standard heart-failure therapy as first-line management for
      dilated cardiomyopathy, of which CMD2A is a genetic form. Evidence source
      is OTHER because this is a Nature Reviews Disease Primers review.
  - reference: PMID:38089682
    reference_title: "Case Report: Mutation in TNNI3(c. 544G>A): a novel likely pathogenic mechanism of neonatal dilated cardiomyopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      He presented repeated weaning difficulties during hospitalization with
      intractable low EF heart insufficiency.
    explanation: >-
      Illustrates the refractoriness of neonatal TNNI3-associated dilated
      cardiomyopathy to supportive and medical management. PARTIAL because this
      patient carried a de novo heterozygous variant rather than a biallelic
      CMD2A genotype.
- name: Mechanical Circulatory Support (ECMO and Ventricular Assist Device)
  description: >-
    The bridge between failing medical therapy and transplantation. When an
    infant with CMD2A decompensates into low-output failure or cardiogenic
    shock, veno-arterial extracorporeal membrane oxygenation provides emergency
    rescue and a ventricular assist device provides durable support until a
    donor organ is available. This step sits between guideline-directed
    pharmacotherapy and heart transplantation in the care pathway, and matters
    disproportionately in this entity because the disease presents in infancy
    with severe, refractory systolic failure and because transplantation is the
    only definitive option.
  therapeutic_modality: DEVICE
  treatment_term:
    preferred_term: mechanical circulatory support as a bridge to transplantation
    term:
      id: NCIT:C80452
      label: Ventricular Assist Device Placement
  target_mechanisms:
  - target: Left Ventricular Dilation and Systolic Failure
    treatment_effect: INHIBITS
    description: >-
      Mechanical support substitutes for the failing ventricle's pump function.
      It does not touch the myofilament lesion; it buys time to transplant.
  notes: >-
    No CMD2A-specific mechanical-support series exists. The evidence below is
    from pediatric dilated cardiomyopathy as a class and is marked PARTIAL
    accordingly. The Sorrentino 2023 CMD2A patients are reported to have
    required ECMO and ventricular assistance before transplantation, but that
    detail is in the paper's full text and is absent from the cached abstract,
    so it is deliberately not quoted here.
  evidence:
  - reference: PMID:42334151
    reference_title: Comparing Outcomes of Heartmate 3 and Heart Transplantation in Older Children With Dilated Cardiomyopathy-Can Transplantation be Delayed or Avoided?
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Children with end-stage dilated cardiomyopathy (DCM) usually undergo heart
      transplantation or a short-term bridge with a ventricular assist device.
    explanation: >-
      Establishes ventricular assist device support as the standard bridge step
      preceding transplantation in end-stage pediatric dilated cardiomyopathy.
      PARTIAL because the registry cohort is children aged 10-18 with DCM of any
      cause, not the infantile recessive TNNI3 subset.
  - reference: PMID:42249650
    reference_title: "Against all odds: Mechanical circulatory support as a bridge to pediatric heart transplant."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      A 12-year-old girl with recurrent cardiac arrests underwent emergency LVAD
      implantation (EXCOR® Active) for 6 h for bridging to HTx.
    explanation: >-
      Documents emergency device implantation as a bridge to transplantation in
      a child with dilated cardiomyopathy and end-stage heart failure. PARTIAL
      because the reported patients are older children with DCM of unstated
      genetic cause rather than confirmed CMD2A.
- name: Heart Transplantation
  description: >-
    The only definitive therapy. Because the lesion is the permanent absence of a
    structural regulatory protein rather than a reversible insult, recovery of
    ventricular function is not expected, and transplantation is the endpoint for
    children who survive to reach it. In the recessive TNNI3 series,
    transplantation has been performed at 28 months for treatment-refractory
    disease.
  therapeutic_modality: SURGERY
  treatment_term:
    preferred_term: heart transplantation
    term:
      id: NCIT:C15246
      label: Heart Transplantation
  evidence:
  - reference: PMID:41918167
    reference_title: A homozygous variant in cardiac troponin I3, TNNI3, causes severe pediatric restrictive cardiomyopathy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The RCM in this patient was treatment refractory and resulted in a heart
      transplant at the age of 28 months.
    explanation: >-
      Documents transplantation as the outcome of treatment-refractory recessive
      TNNI3 cardiomyopathy. PARTIAL because this patient's phenotype was
      restrictive rather than dilated.
- name: Genetic Counseling and Reproductive Options
  description: >-
    Counseling for a 25% sibling recurrence risk, carrier testing of parents and
    at-risk relatives, and discussion of reproductive options. In the reported
    consanguineous kindred, counseling was provided and prenatal diagnosis on
    chorionic villus sampling was offered because preimplantation genetic
    diagnosis was not available. Counseling must also address the fact that
    heterozygous carriers are typically unaffected, which is what makes this
    entity's recurrence pattern differ from that of the dominant TNNI3
    cardiomyopathies.
  therapeutic_modality: BEHAVIORAL
  treatment_term:
    preferred_term: genetic counseling
    term:
      id: NCIT:C15240
      label: Genetic Counseling
  evidence:
  - reference: PMID:38924380
    reference_title: Homozygous TNNI3 frameshift variant in a consanguineous family with lethal infantile dilated cardiomyopathy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Genetic counseling was provided for the family and a prenatal diagnosis of
      choronic villus was proposed in the absence of pre-implantation genetic
      diagnosis possibilities.
    explanation: >-
      Documents genetic counseling and prenatal diagnosis as the applied
      management for recurrence risk in a CMD2A family.
  - reference: PMID:20301486
    reference_title: Dilated Cardiomyopathy Overview.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Provide a basic view of genetic risk assessment of at-risk asymptomatic
      relatives of a proband with DCM to inform cardiac surveillance and allow
      early detection and treatment of DCM to improve long-term outcome.
    explanation: >-
      The GeneReviews DCM overview frames genetic risk assessment of at-risk
      asymptomatic relatives as a purpose of the chapter, supporting cascade
      evaluation as standard practice. PARTIAL on two counts: this is generic
      DCM guidance rather than CMD2A-specific, and the quote is drawn from the
      chapter's stated purpose — the only prose in the PubMed record — rather
      than from a Genetic Counseling section. Evidence source is OTHER because
      GeneReviews is an expert-curated reference work, not a primary study.
experimental_models:
- name: Tnni3-null (cardiac troponin I knockout) mouse
  description: >-
    Germline deletion of the cardiac troponin I isoform by gene targeting in
    murine embryonic stem cells. The reference model for CMD2A, and unusually
    faithful to it: the mice are born healthy under slow skeletal troponin I
    cover, ssTnI declines from day 15, and the animals die of acute heart failure
    on day 18, reproducing the human pattern of a well neonate who decompensates
    once the isoform switch completes. Isolated ventricular myocytes provide the
    myofilament-level readouts (sarcomere length, resting tension, calcium
    sensitivity) that are not obtainable from patients.
  experimental_model_type: OTHER
  organism:
    preferred_term: house mouse
    term:
      id: NCBITaxon:10090
      label: Mus musculus
  cell_types:
  - preferred_term: Cardiomyocyte
    term:
      id: CL:0000746
      label: cardiac muscle cell
  publication: PMID:9915769
  modeled_mechanisms:
  - target: Perinatal Troponin I Isoform Switch and Loss of ssTnI Compensation
    description: >-
      The model's central result is the timing of ssTnI withdrawal in a
      cTnI-null background and the consequent onset of failure.
    evidence:
    - reference: PMID:9915769
      reference_title: "Cardiac troponin I gene knockout: a mouse model of myocardial troponin I deficiency."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        15 days after birth slow skeletal troponin I expression began a steady
        decline, giving rise to a troponin I deficiency
      explanation: >-
        The model's measurement of the ssTnI withdrawal schedule that this
        pathophysiology node describes.
  - target: Thin-Filament Regulatory Failure and Impaired Myofilament Mechanics
    description: >-
      Isolated ventricular myocytes supply the sarcomere-length, resting-tension,
      and calcium-sensitivity measurements of troponin I depletion.
    evidence:
    - reference: PMID:9915769
      reference_title: "Cardiac troponin I gene knockout: a mouse model of myocardial troponin I deficiency."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        Ventricular myocytes isolated from these troponin I-depleted hearts
        displayed shortened sarcomeres and elevated resting tension measured
        under relaxing conditions
      explanation: >-
        The myofilament-mechanics readouts the model contributes to this node.
  evidence:
  - reference: PMID:9915769
    reference_title: "Cardiac troponin I gene knockout: a mouse model of myocardial troponin I deficiency."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      We deleted the cardiac isoform of troponin I by using gene targeting in
      murine embryonic stem cells to determine the developmental and
      physiological effects of the absence of this regulatory protein.
    explanation: >-
      Describes the construction of the model and its purpose, matching the
      genotype of CMD2A (complete absence of cardiac troponin I).
discussions:
- discussion_id: cmd2a_mondo_node_versus_clingen_lumped_dcm
  prompt: >-
    Should CMD2A be curated as its own dismech entity, given that ClinGen curates
    the TNNI3 relationship against the generic "dilated cardiomyopathy" entity
    (MONDO:0005021) and splits it only by mode of inheritance, while MONDO
    maintains a distinct CMD2A node (MONDO:0012746)?
  kind: INTERPRETATION
  status: OPEN
  attaches_to:
  - pathophysiology#Biallelic TNNI3 Loss of Function
  rationale: >-
    ClinGen's Dilated Cardiomyopathy GCEP issued two separate TNNI3-DCM
    assertions on the same day, differing only in mode of inheritance (AD Strong,
    AR Strong), both against MONDO:0005021 — it treats the recessive relationship
    as a distinct curatable claim but not as a distinct disease entity. MONDO
    instead assigns CMD2A its own node with its own OMIM anchor. dismech follows
    MONDO here, and the substantive justification is mechanistic rather than
    nomenclatural: the recessive entity has a different molecular lesion
    (complete loss of function versus dominant-negative/altered-function
    missense), a different age of onset governed by a developmental isoform
    switch, and a different natural history. If ClinGen or MONDO later converges
    on a single lumped TNNI3-cardiomyopathy entity, this entry should be revisited
    rather than duplicated against its dominant siblings.
  evidence:
  - reference: CGGV:assertion_b89182f6-1574-48c6-832f-add41ffbaa4c-2025-04-18T160000.000Z
    reference_title: "TNNI3 / dilated cardiomyopathy (Strong)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      TNNI3 | HGNC:11947 | dilated cardiomyopathy | MONDO:0005021 | AR | Strong
    explanation: >-
      Shows that ClinGen curates the recessive relationship against the generic
      DCM entity rather than against the CMD2A node, which is the tension this
      discussion records.
- discussion_id: cmd2a_truncation_position_phenotype_boundary
  prompt: >-
    Does truncation position within TNNI3 determine whether a biallelic
    loss-of-function genotype produces dilated or restrictive cardiomyopathy, and
    if so where is the boundary?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Thin-Filament Regulatory Failure and Impaired Myofilament Mechanics
  rationale: >-
    The recessive TNNI3 series is currently modeled as producing dilated
    cardiomyopathy, but a homozygous distal nonsense allele (p.Arg136*) with
    diminished-but-detectable myocardial protein has been reported to produce
    restrictive cardiomyopathy instead. That single observation implies a graded
    residual-function relationship rather than a binary null state, but it is one
    patient, the protein-abundance measurement is semiquantitative, and no
    systematic genotype-to-phenotype series across truncation positions exists.
    Until it does, dismech should not assert a positional rule.
  proposed_experiments:
  - experiment_id: exp_cmd2a_truncation_position_genotype_series
    name: Multi-center biallelic TNNI3 truncation-position genotype-phenotype series
    description: >-
      Assemble a multi-center series of biallelic TNNI3 loss-of-function patients
      annotated by truncation position, cardiomyopathy subtype, and age of onset,
      to test whether phenotype tracks predicted residual protein length.
  - experiment_id: exp_cmd2a_residual_ctni_quantification
    name: Quantification of residual cTnI across recessive truncating alleles
    description: >-
      Quantify cTnI protein abundance and thin-filament incorporation in
      myocardial tissue or patient-derived iPSC-cardiomyocytes across the reported
      truncating alleles, to establish whether residual function is measurable
      rather than inferred.
  evidence:
  - reference: PMID:41918167
    reference_title: A homozygous variant in cardiac troponin I3, TNNI3, causes severe pediatric restrictive cardiomyopathy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Overall, recessive TNNI3 protein truncation causes severe pediatric RCM,
      suggesting that the allelic status, type of genetic alteration, and length
      of TNNI3 protein truncation determine cardiomyopathy onset and subtype
      manifestation.
    explanation: >-
      States the proposed positional rule as a suggestion drawn from a single
      patient — the open question this discussion records.
- discussion_id: cmd2a_sstni_compensation_human_fidelity
  prompt: >-
    Does the murine slow-skeletal-troponin-I compensation-then-withdrawal
    mechanism, which supplies the timing explanation for CMD2A, actually operate
    on the same schedule in the human heart?
  kind: HUMAN_MODEL_MISMATCH
  status: OPEN
  attaches_to:
  - pathophysiology#Perinatal Troponin I Isoform Switch and Loss of ssTnI Compensation
  rationale: >-
    The isoform-switch explanation for why a cTnI-null child is well at birth and
    fails weeks later rests almost entirely on the Tnni3-null mouse, where the
    schedule is sharp and well characterized (ssTnI decline from day 15, death on
    day 18). The human TnI isoform switch is known to occur perinatally, but no
    direct measurement of ssTnI persistence in the myocardium of a CMD2A patient
    has been reported, and the human presentation window is broader — neonatal in
    some reports, later in the first year in others. Whether that variability
    reflects individual differences in the timing of ssTnI withdrawal, residual
    cTnI from hypomorphic alleles, or unrelated modifiers is unresolved. This is a
    model-fidelity question, not an absence of evidence: the mouse result is
    strong, its human transferability is the open item.
  proposed_experiments:
  - experiment_id: exp_cmd2a_human_myocardial_sstni_timing
    name: Myocardial ssTnI/cTnI abundance across CMD2A patient ages
    description: >-
      Measure ssTnI and cTnI protein abundance in myocardial tissue obtained at
      transplantation or autopsy from CMD2A patients of differing ages, to test
      whether clinical decompensation coincides with ssTnI withdrawal.
  - experiment_id: exp_cmd2a_ipsc_tni_isoform_schedule
    name: TnI isoform schedule in TNNI3-null human iPSC-cardiomyocytes
    description: >-
      Track TnI isoform composition during maturation of TNNI3-null
      iPSC-cardiomyocytes or engineered heart tissue against isogenic controls,
      to establish the human schedule in a controlled system.
  evidence:
  - reference: PMID:9915769
    reference_title: "Cardiac troponin I gene knockout: a mouse model of myocardial troponin I deficiency."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Compensation was only temporary, however, as 15 days after birth slow
      skeletal troponin I expression began a steady decline, giving rise to a
      troponin I deficiency.
    explanation: >-
      Supplies the precise murine schedule whose human counterpart has not been
      directly measured.
  - reference: PMID:26526134
    reference_title: "TNNI1, TNNI2 and TNNI3: Evolution, regulation, and protein structure-function relationships."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      which are expressed under muscle type-specific and developmental
      regulations
    explanation: >-
      Confirms that TnI isoform expression is developmentally regulated in
      vertebrates generally. PARTIAL because it does not supply a human
      myocardial timing measurement.
references:
- reference: PMID:20301486
  title: Dilated Cardiomyopathy Overview.
  tags:
  - GeneReviews
notes: >-
  GeneReviews baseline: no CMD2A- or TNNI3-specific GeneReviews chapter exists.
  The applicable chapter is the generic "Dilated Cardiomyopathy Overview"
  (PMID:20301486, Hershberger & Jordan, updated 2024), tagged above. Its PubMed
  record contains only the chapter's stated purpose and no Clinical
  Characteristics text, so it could not be used as a phenotype baseline; the
  phenotype set here is built from the primary CMD2A case literature and the
  Sorrentino review of biallelic TNNI3 loss-of-function patients instead.

  Scope note: this entry is deliberately restricted to the recessive,
  loss-of-function TNNI3 entity. The dominant TNNI3 missense diseases
  (hypertrophic CMH7, restrictive RCM1) are recorded here only as differential
  diagnoses and spectrum context, and belong to the Hypertrophic_Cardiomyopathy
  and restrictive entries respectively. PMID:38089682 is cited twice, for
  imaging findings and for treatment refractoriness in neonatal
  TNNI3-associated DCM, but that patient carried a de novo heterozygous variant
  with no variant in either parent, so it is not a CMD2A genotype; both
  citations are marked PARTIAL and the limitation is stated in each
  explanation.

  Curation caution — TNNI3 is not TNNI3K. TNNI3K (troponin I-interacting
  kinase, HGNC:19661) is a separate gene with its own, independently curated
  ClinGen DCM gene-disease relationship. TNNI3K knockout and cardiac-remodeling
  literature must not be used as evidence for this entry; it surfaced as a
  near-miss during the deep-research pass for this disorder.

  Deep-research provenance: Edison/FutureHouse Falcon
  (research/Dilated_Cardiomyopathy_2A-deep-research-falcon.md, 17 citations).
  The report was used as a lead-generation source only; every PMID, snippet, and
  ontology term in this entry was independently verified against the cached
  abstract or against OAK. Two Falcon claims were checked and NOT carried over:
  its assertion that both Sorrentino 2023 patients carried homozygous p.Arg98*
  (the abstract states one carried p.Arg98* and the other p.Arg69Alafs*8), and
  its report of compensatory TNNI1 upregulation in affected human myocardium,
  which is not stated in any abstract available in the reference cache. Falcon
  also failed to recover a MONDO identifier; MONDO:0012746 was resolved directly
  with OAK and matches the OMIM:611880 and TNNI3 anchors in the MONDO record.
📚

References & Deep Research

References

1
PMID:20301486
Dilated Cardiomyopathy Overview.
No top-level findings curated for this source.

Deep Research

1
Falcon ▸
Dilated Cardiomyopathy 2A (DCM2A): Disease Characteristics Report
Edison Scientific Literature 17 citations 2026-08-02T16:55:30.717974

Dilated Cardiomyopathy 2A (DCM2A): Disease Characteristics Report

Executive summary and evidence boundary

Dilated cardiomyopathy 2A (DCM2A; also written CMD2A) is an exceptionally rare, usually neonatal or infantile, autosomal-recessive cardiomyopathy caused by biallelic loss-of-function variants in TNNI3, which encodes cardiac troponin I (cTnI). It should not be conflated with dominant hypertrophic, restrictive, or dilated cardiomyopathies caused by heterozygous TNNI3 alleles, or with disease involving the separate kinase gene TNNI3K. The strongest disease-specific synthesis available in the retrieved literature is Sorrentino et al., published March 2023, DOI 10.3390/genes14030748. It summarized only 20 individuals with biallelic TNNI3 variants; 16 had DCM, sometimes overlapping left-ventricular noncompaction (LVNC). Consequently, most frequencies and prognosis estimates remain imprecise, and treatment recommendations are necessarily extrapolated from pediatric/genetic DCM practice. (sorrentino2023homozygoustnni3mutations pages 8-9, sorrentino2023homozygoustnni3mutations pages 1-2)

Topic DCM2A-specific summary General DCM context / extrapolation Suggested ontology terms / identifiers Key citations
Definition / scope Dilated cardiomyopathy 2A (DCM2A; historically CMD2A) is a rare autosomal recessive cardiomyopathy caused by biallelic TNNI3 loss-of-function variants, usually presenting as severe neonatal/infantile dilated cardiomyopathy; broader heterozygous TNNI3-associated cardiomyopathies are a different entity. Broader DCM is genetically heterogeneous and includes monogenic, oligogenic, and acquired forms. OMIM: 611880; suggested disease terms: dilated cardiomyopathy, infantile-onset cardiomyopathy (sorrentino2023homozygoustnni3mutations pages 2-4, newman2024dilatedcardiomyopathya pages 1-2)
Causal gene and inheritance TNNI3 (cardiac troponin I) is the established causal gene for DCM2A when variants are biallelic and loss-of-function; inheritance is autosomal recessive. Consanguinity is reported in some families but is not required. In general DCM, pathogenic variants are found in many genes; pediatric cases often have higher genetic diagnostic yield than adult cases. Gene: TNNI3; suggested HGNC symbol: TNNI3; inheritance: AR (sorrentino2023homozygoustnni3mutations pages 5-8, sorrentino2023homozygoustnni3mutations pages 2-4, eldemire2024geneticsofdilated pages 1-3)
Hallmark phenotype / onset Hallmark presentation is early severe systolic dysfunction with LV dilation, often in the first months of life, with low LVEF, heart failure symptoms (dyspnea, feeding difficulty), and occasional LV noncompaction overlap. Disease course is usually rapidly progressive. General pediatric DCM can present across childhood, but infancy is a particularly vulnerable period. HPO: Dilated cardiomyopathy HP:0001644; Left ventricular systolic dysfunction HP:0005162; Heart failure HP:0001635; Dyspnea HP:0002094; Feeding difficulties HP:0011968; Left ventricular noncompaction HP:0006677 (sorrentino2023homozygoustnni3mutations pages 8-9, sorrentino2023homozygoustnni3mutations pages 4-5, sorrentino2023homozygoustnni3mutations pages 5-8)
Strongest disease-specific statistics In the 2023 disease-focused review/case series, 20 documented biallelic TNNI3 cases were summarized, of which 16/20 had DCM phenotype; onset was consistently early and outcomes were typically severe, often requiring transplant soon after diagnosis. By contrast, general genetic DCM is much more common and genetically diverse; up to ~40% of idiopathic/familial DCM has an identifiable genetic basis. Evidence type: human case reports / case series (sorrentino2023homozygoustnni3mutations pages 8-9, newman2024dilatedcardiomyopathya pages 1-2, eldemire2024geneticsofdilated pages 1-3)
Recurrent variants and frequencies Recurrent DCM2A-associated variants include p.Arg69Alafs*8 and p.Arg98*. Reported carrier frequencies in population data summarized in the 2023 review were approximately 1/26,222 for p.Arg69Alafs*8 and 1/17,750 for p.Arg98*; healthy heterozygous carrier frequency overall was summarized as 48/100,000. In two 2023 patients, homozygous c.292C>T (p.Arg98*) caused severe infantile DCM. Heterozygous TNNI3 variants more commonly relate to hypertrophic/restrictive cardiomyopathy and do not define DCM2A. Variant classes: nonsense, frameshift, splice-altering / null (sorrentino2023homozygoustnni3mutations pages 8-9, sorrentino2023homozygoustnni3mutations pages 4-5, sorrentino2023homozygoustnni3mutations pages 1-2)
Mechanism / pathophysiology Core mechanism is loss of cTnI function due to biallelic TNNI3 null variants, often through nonsense-mediated decay with markedly reduced or absent TNNI3 mRNA/protein in myocardium; compensatory upregulation of fetal TNNI1 has been reported. Expected downstream effect is impaired sarcomeric thin-filament inhibition and abnormal excitation-contraction coupling leading to contractile failure, ventricular dilation, and heart failure. General DCM literature supports sarcomeric dysfunction, calcium-handling abnormalities, remodeling, fibrosis, and arrhythmia susceptibility as common downstream pathways. GO: sarcomere organization GO:0045214; cardiac muscle contraction GO:0060048; regulation of cardiac muscle contraction by calcium ion signaling GO:0010882; CL: cardiomyocyte CL:0002494; UBERON: heart UBERON:0000948, left ventricle UBERON:0002084 (sorrentino2023homozygoustnni3mutations pages 5-8, sorrentino2023homozygoustnni3mutations pages 8-9, newman2024dilatedcardiomyopathya pages 1-2)
Diagnosis Most disease-specific diagnoses have been made by echocardiography plus molecular testing. Practical approach: infant/pediatric cardiomyopathy work-up with ECG, echocardiography, family history, and multigene panel / WES, interpreted with genetic counseling; test the most clearly affected proband first, then cascade test relatives if a familial variant is found. This diagnostic strategy is extrapolated from pediatric/genetic DCM practice, where genetic testing is recommended and informative for prognosis and family screening. Suggested tests: echocardiography, ECG, cardiac MRI when feasible, multigene cardiomyopathy panel, WES/WGS as needed (sorrentino2023homozygoustnni3mutations pages 4-5, arnautu2024riskassessmentand pages 11-12, eldemire2024geneticsofdilated pages 1-3)
Treatment / prognosis No approved TNNI3-specific therapy was identified. Reported DCM2A patients were managed with advanced heart-failure care; severe infant cases often required ECMO/VAD bridge and heart transplantation, with favorable post-transplant short-term outcomes in the two 2023 cases. Overall prognosis appears poor without advanced support because progression is often rapid. Extrapolated standard DCM/HFrEF care includes beta-blocker, ARNI/ACEi/ARB, MRA, and SGLT2 inhibitor when age/clinical status allow; refractory pediatric cases may need mechanical support/transplant. NCIT suggestions: Heart Transplantation, Ventricular Assist Device, Extracorporeal Membrane Oxygenation, Genetic Counseling (sorrentino2023homozygoustnni3mutations pages 4-5, arnautu2024riskassessmentand pages 21-23, mestroni2014geneticcausesof pages 6-8)
Prevention / risk modification No primary prevention exists for genetically affected homozygotes beyond reproductive counseling and at-risk family identification. Secondary prevention is cascade screening of relatives and early cardiac surveillance in genetically at-risk family members. General DCM counseling includes avoiding cardiotoxic exposures and recognizing that pregnancy, alcohol, chemotherapy, and other triggers can worsen some genetic DCMs, though this has not been shown specifically for DCM2A. Suggested counseling terms: cascade screening, reproductive counseling, family screening (arnautu2024riskassessmentand pages 11-12, mestroni2014geneticcausesof pages 6-8, bondue2018complexroadsfrom pages 19-22)
Major evidence gaps Very small number of published patients; phenotype frequencies remain imprecise; penetrance estimates for heterozygous relatives are uncertain; no confidently retrieved MONDO/Orphanet ID; no disease-specific biomarker, natural-history registry, or approved targeted therapy identified; no well-validated DCM2A-specific animal model was retrieved, and TNNI3K studies must not be confused with TNNI3 disease biology. General DCM research is rapidly evolving, but its findings cannot be assumed to apply directly to recessive TNNI3-null infantile disease. Curation note: do not infer TNNI3K knockout data as DCM2A evidence (qu2022knockoutofcardiac pages 7-7, sorrentino2023homozygoustnni3mutations pages 8-9, arnautu2024riskassessmentand pages 11-12)

Table: This table compacts the highest-yield knowledge-base facts for Dilated Cardiomyopathy 2A, separating subtype-specific evidence from broader dilated cardiomyopathy context. It is useful for rapid curation of identifiers, phenotype, mechanism, diagnosis, and current evidence gaps.

1. Disease information

Definition

DCM2A is a primary genetic myocardial disease characterized by ventricular—usually left-ventricular—dilation, severe systolic dysfunction, and rapidly progressive heart failure after biallelic TNNI3 loss of function. Cardiac troponin I is the inhibitory subunit of the thin-filament troponin complex and is essential for calcium-regulated cardiac contraction and relaxation. (sorrentino2023homozygoustnni3mutations pages 5-8, sorrentino2023homozygoustnni3mutations pages 2-4)

Identifiers and synonyms

  • OMIM: 611880, Cardiomyopathy, dilated, 2A.
  • Common names: DCM2A, CMD2A, cardiomyopathy dilated 2A, autosomal-recessive TNNI3-related dilated cardiomyopathy, recessive cardiac troponin-I cardiomyopathy.
  • MONDO: a unique DCM2A-specific MONDO identifier was not confidently recoverable; map provisionally to the relevant MONDO dilated-cardiomyopathy concept while retaining OMIM:611880 as the subtype identifier.
  • Orphanet: no confidently verified subtype-specific identifier was found.
  • ICD-10-CM: I42.0, dilated cardiomyopathy; no gene-specific code.
  • ICD-11: use the dilated-cardiomyopathy category with genetic etiology annotation; no dedicated DCM2A code was verified.
  • MeSH: Cardiomyopathy, Dilated.

The evidence is mainly aggregated disease-level literature assembled from individual case reports and small families, not population EHR cohorts. The 2023 report combined two new patients with previously published cases. (sorrentino2023homozygoustnni3mutations pages 8-9, sorrentino2023homozygoustnni3mutations pages 4-5, sorrentino2023homozygoustnni3mutations pages 2-4)

2. Etiology, risk, protective factors, and gene–environment interaction

Primary causal factor

The established cause is a germline biallelic pathogenic TNNI3 genotype, especially nonsense, frameshift, or splice-disrupting alleles that abolish cTnI expression. Autosomal-recessive segregation was first supported by affected siblings of consanguineous parents; subsequent unrelated families consolidated the association. (sorrentino2023homozygoustnni3mutations pages 5-8, sorrentino2023homozygoustnni3mutations pages 2-4)

Genetic risk factors

  • Having two pathogenic TNNI3 alleles is the principal risk factor.
  • Parental consanguinity increases the chance that a rare allele is inherited homozygously, but DCM2A also occurs in nonconsanguineous families.
  • Recurrent alleles include p.Arg69Alafs8 and p.Arg98. In the 2023 synthesis, p.Arg69Alafs* occurred in 9 of 16 families; estimated carrier frequencies were approximately 1/26,222 and 1/17,750, respectively. Aggregate healthy heterozygous carriage was estimated at 48/100,000. These are carrier—not disease-prevalence—figures. (sorrentino2023homozygoustnni3mutations pages 8-9, sorrentino2023homozygoustnni3mutations pages 4-5)
  • No validated modifier gene or polygenic score specific to DCM2A has been established.

Environmental and protective factors

No environmental exposure is known to cause DCM2A, and no genetic protective allele has been validated. Avoiding alcohol excess, cocaine/amphetamines, cardiotoxic chemotherapy, smoking, obesity, and uncontrolled hypertension is prudent in genetic DCM generally, but evidence is not TNNI3-null-specific. Pregnancy, viral myocarditis, alcohol, and anthracyclines can interact with susceptibility alleles in broader DCM; equivalent gene–environment interaction data for DCM2A are absent. (arnautu2024riskassessmentand pages 21-23, mestroni2014geneticcausesof pages 6-8, bondue2018complexroadsfrom pages 19-22)

3. Phenotypes

Core disease-specific phenotype

Manifestation Type and suggested HPO term Characteristics
Dilated cardiomyopathy Sign/imaging; HP:0001644 Present in 16/20 reported biallelic cases in the 2023 synthesis; predominantly neonatal/infantile, severe, progressive.
LV dilation/cardiomegaly Imaging/sign; HP:0001711 (abnormal LV morphology), HP:0001640 (cardiomegaly) Often marked at presentation.
LV systolic dysfunction/low EF Functional abnormality; HP:0005162 Two 2023 infants had LVEF 25%; typically refractory.
Congestive heart failure Clinical syndrome; HP:0001635 Rapid progression; advanced mechanical support or transplantation is common.
Dyspnea/tachypnea Symptom; HP:0002094, HP:0002789 Common presenting manifestation in infancy.
Feeding difficulty/poor intake Symptom; HP:0011968 Reported in an infant at six months.
Mitral/tricuspid regurgitation Imaging/sign; HP:0001653, HP:0005180 Functional regurgitation may accompany chamber dilation.
LV noncompaction overlap Imaging; HP:0006677 Reported in a minority; exact frequency is uncertain.
Cardiogenic shock Acute sign; HP:0030149 Severe cases may require ECMO/VAD.

The reviewed homozygous null genotypes showed relatively little variability and generally severe outcomes. Missense alleles with residual activity may have slower or atypical courses, including restrictive phenotypes; they should not automatically be grouped with null-allele DCM2A. (sorrentino2023homozygoustnni3mutations pages 8-9, sorrentino2023homozygoustnni3mutations pages 4-5)

Illustrative human cases

A seven-month-old child had dyspnea, LV dilation, and LVEF 25%, then required ECMO and ventricular assistance; an ischemic stroke complicated support, followed by transplantation and post-transplant LVEF 61%. A second child presented at six months with feeding difficulty, dyspnea, severe left-sided dilation, LVEF 25%, and mitral/tricuspid insufficiency; transplantation at eight months produced a favorable early outcome. Both reports involved homozygous c.292C>T (p.Arg98*). (sorrentino2023homozygoustnni3mutations pages 4-5)

Quality of life

No DCM2A-specific EQ-5D, SF-36, PedsQL, or PROMIS study exists. Severe heart failure is expected to impair feeding, growth, activity, sleep, and caregiver/family functioning, while hospitalization, mechanical support, and transplantation impose major burdens. These effects are clinically evident but have not been quantified in this subtype.

4. Genetic and molecular information

Causal gene

  • Gene: TNNI3, troponin I3, cardiac type.
  • Protein: cardiac troponin I, the inhibitory component of the troponin complex.
  • Disease mechanism: biallelic loss of function.
  • Origin: constitutional/germline, not somatic.

Pathogenic variants

The strongest DCM2A variants are rare biallelic null alleles: nonsense, frameshift, and splice-altering variants. In affected myocardium, premature-termination variants can undergo nonsense-mediated decay, producing markedly reduced TNNI3 RNA and complete absence of cTnI protein. The fetal slow-skeletal isoform TNNI1 may be compensatorily increased but does not prevent severe disease. (sorrentino2023homozygoustnni3mutations pages 8-9, sorrentino2023homozygoustnni3mutations pages 5-8)

Important reported alleles include:

  • c.292C>T, p.Arg98*: nonsense; homozygous in severe infantile DCM. It was present heterozygously in gnomAD at approximately 1/9,187 among non-Finnish Europeans in the cited analysis; heterozygosity alone is insufficient to establish DCM2A. (sorrentino2023homozygoustnni3mutations pages 4-5)
  • p.Arg69Alafs*8: recurrent frameshift/null allele; approximate allele/carrier frequency 1/26,222 in the 2023 synthesis. (sorrentino2023homozygoustnni3mutations pages 8-9, sorrentino2023homozygoustnni3mutations pages 5-8)
  • p.Ala2Val: homozygous in the first reported recessive family, although the precise residual function and classification require variant-level reassessment under current ACMG/AMP criteria. (sorrentino2023homozygoustnni3mutations pages 5-8)

A variant should be classified with ACMG/AMP criteria using segregation, phenotype specificity, population frequency, predicted transcript effect, myocardial/RNA functional evidence, and ClinVar expert assertions where available. A VUS must not be used for predictive testing or reproductive decision-making as though pathogenic.

Other molecular categories

No recurrent DCM2A-specific chromosomal rearrangement, aneuploidy, somatic mechanism, DNA-methylation signature, or validated modifier gene has been demonstrated. Copy-number analysis remains relevant if sequencing detects only one pathogenic allele. Large deletions affecting TNNI3 would be biologically plausible but were not established as a common mechanism in the retrieved evidence.

5. Environmental and lifestyle information

DCM2A is genetic rather than infectious, toxic, occupational, or radiation-induced. No pathogen is causally implicated. Standard management should nevertheless exclude potentially reversible contributors such as myocarditis, endocrine/metabolic disease, nutritional deficiency, tachyarrhythmia, and toxic exposure. For genetically susceptible DCM generally, limiting alcohol and avoiding cocaine, amphetamines, and unnecessary cardiotoxic drugs is recommended; moderate, clinician-directed physical activity is preferable to inactivity, but exercise must be individualized in advanced pediatric heart failure. (arnautu2024riskassessmentand pages 21-23, mestroni2014geneticcausesof pages 6-8)

6. Mechanism and pathophysiology

Causal chain

  1. Upstream genetic lesion: two damaging TNNI3 alleles.
  2. Transcript/protein defect: nonsense-mediated decay or unstable/truncated transcript causes absent or markedly reduced cTnI.
  3. Sarcomeric defect: the troponin complex loses normal inhibition of actin–myosin interaction at low cytosolic calcium and normal modulation of thin-filament activation.
  4. Cellular dysfunction: abnormal calcium–myofilament coupling, impaired relaxation/contractile reserve, inefficient force production, and cardiomyocyte stress.
  5. Tissue remodeling: chamber dilation, reduced systolic performance, neurohormonal activation, secondary valvular regurgitation, and potentially fibrosis/arrhythmia.
  6. Clinical endpoint: severe infantile heart failure, cardiogenic shock, mechanical-support dependence, transplantation, or death. (sorrentino2023homozygoustnni3mutations pages 8-9, sorrentino2023homozygoustnni3mutations pages 5-8, sorrentino2023homozygoustnni3mutations pages 2-4)

The first two steps are directly supported in DCM2A myocardium; detailed calcium, metabolic, immune, and fibrosis pathways are largely inferred from troponin biology and general DCM. It would be inappropriate to assign a specific Wnt, MAPK, mTOR, or PI3K–AKT driver to human DCM2A without direct evidence.

Cells, tissues, and ontology suggestions

  • Primary cell: cardiac muscle cell/cardiomyocyte, CL:0000746 (cardiac muscle cell; ontology releases may also expose more specific ventricular cardiomyocyte descendants).
  • GO biological processes: cardiac muscle contraction GO:0060048; regulation of cardiac muscle contraction GO:0055117; sarcomere organization GO:0045214; muscle filament sliding GO:0030049; calcium-mediated signaling GO:0019722; regulation of heart contraction GO:0008016.
  • GO cellular components: sarcomere GO:0030017; myofibril GO:0030016; troponin complex GO:0005861; thin filament GO:0005865.

Molecular profiling and advanced technologies

Disease-specific single-cell, spatial-transcriptomic, proteomic, metabolomic, lipidomic, or integrated multi-omic studies were not found. Direct myocardial assays showing absent TNNI3 and increased TNNI1 are the most relevant expression/protein observations. RNA sequencing can be diagnostically valuable for suspected splice variants, but it is not a routine validated biomarker. No DCM2A-specific CRISPR screen was identified. (sorrentino2023homozygoustnni3mutations pages 8-9, sorrentino2023homozygoustnni3mutations pages 5-8)

7. Anatomical structures affected

  • Primary organ: heart, UBERON:0000948.
  • Primary chamber: left ventricle, UBERON:0002084; biventricular disease can develop.
  • Tissue: myocardium UBERON:0002349, particularly ventricular myocardium.
  • Cell: ventricular cardiomyocyte/cardiac muscle cell.
  • Subcellular site: sarcomere, myofibril, thin filament, troponin complex.
  • Secondary organs: lungs through pulmonary congestion/hypertension; liver, kidneys, and brain through advanced low-output failure or treatment complications. The reported ischemic stroke occurred during advanced support and is not necessarily a primary DCM2A phenotype. (sorrentino2023homozygoustnni3mutations pages 4-5)
  • Lateralization: not applicable; myocardial disease is not unilateral, although LV dysfunction predominates.

8. Temporal development

Onset is usually congenital, neonatal, or in the first year of life; six- and seven-month presentations are documented. The course is chronic but often rapidly progressive rather than episodic. A useful clinical staging model is: genotype-positive/presymptomatic → subtle chamber or functional abnormality → overt DCM with reduced EF → advanced/refractory heart failure → VAD/transplantation or death. Homozygous null cases commonly reach advanced stages shortly after recognition. Durable spontaneous remission has not been demonstrated; improvement after transplantation reflects organ replacement rather than correction of the genotype. (sorrentino2023homozygoustnni3mutations pages 8-9, sorrentino2023homozygoustnni3mutations pages 4-5, sorrentino2023homozygoustnni3mutations pages 1-2)

The critical intervention window is therefore before or at the earliest sign of ventricular dysfunction in an at-risk sibling. Serial surveillance should not wait for symptoms.

9. Inheritance and population

Inheritance

DCM2A is autosomal recessive. For two confirmed heterozygous parents, each pregnancy has a 25% probability of an affected child, 50% probability of a heterozygous carrier, and 25% probability of inheriting neither familial allele. Penetrance appears high for biallelic null genotypes but cannot be quantified reliably from the small, ascertainment-biased literature. Expressivity is severe and relatively consistent for null alleles, but residual-function alleles can produce variable DCM, LVNC, or restrictive phenotypes. Anticipation is not expected. Germline mosaicism has not been established but cannot be excluded after an apparently de novo result. Consanguinity is relevant but not necessary. (sorrentino2023homozygoustnni3mutations pages 8-9, sorrentino2023homozygoustnni3mutations pages 4-5, sorrentino2023homozygoustnni3mutations pages 5-8)

Epidemiology

No population prevalence or incidence is available for DCM2A. Only approximately 20 biallelic cases had been summarized by 2023, so it qualifies as ultra-rare. Variant carrier frequencies must not be converted into disease prevalence without accounting for allelic heterogeneity and penetrance. (sorrentino2023homozygoustnni3mutations pages 8-9)

For context only, general DCM prevalence estimates range widely, from 36.5 per 100,000 in older epidemiology to over 0.4% in newer imaging-based estimates; incidence near 7 per 100,000/year has been cited. These figures do not describe DCM2A. General pediatric DCM has a higher incidence in infancy, and one 2024 genetics review reported a molecular diagnosis in 54% of pediatric versus 27% of adult DCM. (newman2024dilatedcardiomyopathya pages 1-2, mestroni2014geneticcausesof pages 1-3, eldemire2024geneticsofdilated pages 1-3)

No reproducible ethnic, geographic, or sex enrichment has been established for DCM2A. Reported families include European and North African ancestry, reflecting case ascertainment rather than prevalence.

10. Diagnostics

Clinical evaluation

  1. Echocardiography: chamber dimensions, fractional shortening/LVEF, valvular regurgitation, RV function, and LVNC morphology.
  2. ECG and ambulatory monitoring: conduction disease, atrial/ventricular arrhythmia, and repolarization abnormalities.
  3. Cardiac MRI: ventricular volumes/function, LVNC, edema, and late-gadolinium enhancement when feasible and safe.
  4. Laboratory assessment: BNP/NT-proBNP and troponin for severity/injury; CBC, electrolytes, renal/liver/thyroid testing, creatine kinase, lactate, acylcarnitines, and other metabolic testing guided by age and presentation. No laboratory biomarker is specific to DCM2A.
  5. Endomyocardial biopsy: not required for routine genetic diagnosis; consider only when myocarditis, storage disease, infiltrative disease, or an actionable histological diagnosis remains plausible.

Genetic testing algorithm

A comprehensive cardiomyopathy panel including TNNI3 is generally the first-line molecular test. Ensure reliable coverage of coding exons, splice boundaries, and copy-number changes. Trio WES is especially useful in severe infantile disease; WGS can detect deep-intronic and structural variants missed by panels/WES. If one allele or a suspected splice variant remains unresolved, RNA analysis from an informative tissue may help. Karyotype, FISH, chromosomal microarray, mitochondrial sequencing, and repeat-expansion testing are not first-line for isolated DCM2A but may be appropriate for syndromic presentations. A negative test does not exclude hereditary DCM. (eldemire2024geneticsofdilated pages 1-3, arnautu2024riskassessmentand pages 11-12)

The most affected individual should be tested first, followed by targeted parental segregation and cascade testing. In a national pediatric DCM cohort, 38/107 tested children (36%) had a pathogenic/likely pathogenic variant, and variant-positive children had a higher death/transplant risk (HR 2.8, 95% CI 1.3–5.8); these are general pediatric DCM data supporting routine genetic evaluation, not TNNI3-specific estimates. (eldemire2024geneticsofdilated pages 1-3)

Differential diagnosis

Exclude myocarditis; anomalous coronary origin; congenital structural disease; tachycardia-induced cardiomyopathy; metabolic/mitochondrial disorders; Barth syndrome; carnitine deficiency; neuromuscular disease; sepsis; endocrine disease; toxic cardiomyopathy; and other monogenic DCM. Dominant TNNI3-associated hypertrophic/restrictive cardiomyopathy differs by genotype, ventricular morphology, and inheritance.

Screening

There is no newborn biochemical screen. Siblings and other at-risk relatives require genetic counseling, targeted testing for known familial alleles, and phenotype screening with history, examination, ECG, and echocardiography. Prenatal diagnosis and preimplantation genetic testing are technically possible once both familial pathogenic variants are established.

11. Outcome and prognosis

Disease-specific prognosis is unfavorable for biallelic null genotypes. Early onset, severely depressed EF, escalation to inotropes/ECMO/VAD, and inability to recover ventricular function indicate high transplant/death risk. In the two 2023 patients, transplantation produced favorable early cardiac outcomes, but no DCM2A-specific five- or ten-year survival estimate exists. (sorrentino2023homozygoustnni3mutations pages 8-9, sorrentino2023homozygoustnni3mutations pages 4-5)

General pediatric DCM should not substitute for subtype-specific prognosis, although it provides context: a 2024 review cited 94% five-year survival but a 38% transplantation rate in genetically characterized pediatric disease. Broader nonischemic DCM cohorts have reported major cardiac events in about 50% over 12 years and death/transplant/VAD in 17% over eight years. (newman2024dilatedcardiomyopathya pages 1-2, eldemire2024geneticsofdilated pages 1-3)

Major morbidities include recurrent hospitalization, growth and feeding impairment, arrhythmia, thromboembolism, secondary valve regurgitation, pulmonary hypertension, end-organ dysfunction, and complications of mechanical support/transplantation. No validated DCM2A-specific prognostic biomarker exists; phenotype severity and trajectory currently dominate risk assessment.

12. Treatment

Current treatment

There is no approved therapy that restores TNNI3 in DCM2A. Management should occur in a pediatric advanced-heart-failure and inherited-cardiomyopathy center.

  • Congestion: loop diuretics; NCIT concept suggestion: Diuretic Therapy.
  • Chronic systolic failure: age-appropriate ACE inhibitor/ARB or ARNI, evidence-based beta-blocker, mineralocorticoid-receptor antagonist, and—in selected older pediatric patients under specialist protocols—an SGLT2 inhibitor. The four-class regimen is established principally in adult HFrEF; pediatric dosing and evidence differ. (arnautu2024riskassessmentand pages 21-23, mestroni2014geneticcausesof pages 6-8)
  • Acute decompensation: oxygen/ventilation, inotropes, vasopressors, and intensive monitoring as indicated.
  • Mechanical support: ECMO and ventricular-assist devices as rescue or bridge to transplant; both were clinically relevant in reported DCM2A. Suggested NCIT terms: Extracorporeal Membrane Oxygenation; Ventricular Assist Device. (sorrentino2023homozygoustnni3mutations pages 4-5)
  • Transplantation: definitive therapy for refractory end-stage disease; suggested NCIT term: Heart Transplantation.
  • Arrhythmia/device therapy: individualized Holter surveillance, antiarrhythmics, pacing, or ICD based on phenotype. Unlike LMNA/FLNC/PLN disease, no TNNI3-specific threshold supports prophylactic ICD implantation. (arnautu2024riskassessmentand pages 21-23)
  • Supportive care: nutrition, vaccination, psychosocial support, physical/occupational therapy for deconditioning, and transplant rehabilitation.

Experimental and precision therapy

No DCM2A-specific interventional clinical trial was found. AAV-mediated TNNI3 replacement, transcript rescue, and genome editing are biologically plausible but remain preclinical concepts. The principal challenges are cardiac delivery, dose control, immune responses, developmental timing, and avoiding abnormal troponin stoichiometry. Genotype currently informs diagnosis, recurrence risk, family screening, and urgency—not selection of an approved TNNI3-targeted drug.

Pharmacogenomic associations involving ADRB1, GRK5, ACE, and AGTR1 have been described in broader DCM/HFrEF, but routine use to guide DCM2A therapy lacks clinical validity. (arnautu2024riskassessmentand pages 21-23)

13. Prevention

  • Primary prevention: the genotype cannot be prevented after conception. Preconception counseling, carrier testing of partners in relevant families, IVF with preimplantation genetic testing, donor gametes, prenatal diagnosis, or natural conception with informed testing are reproductive options.
  • Secondary prevention: early cascade testing and scheduled ECG/echocardiography can detect presymptomatic disease and permit earlier therapy. This is the most actionable prevention strategy. (arnautu2024riskassessmentand pages 11-12)
  • Tertiary prevention: guideline-directed heart-failure care, vaccination, nutrition, arrhythmia/thromboembolism assessment, avoidance of cardiotoxins, and timely referral for mechanical support/transplantation.
  • Immunization: no disease-specific vaccine; routine respiratory vaccination is valuable in medically fragile heart-failure patients.
  • Public health: no population-wide newborn or carrier-screening program is justified by current evidence. Real-world genetic testing remains underused: only 827/101,919 newly diagnosed DCM patients (0.8%) in a large US EHR/claims study had documented testing within six months, underscoring an implementation gap, though the cohort was not DCM2A-specific. (arnautu2024riskassessmentand pages 11-12)

14. Other species and natural disease

No convincing naturally occurring TNNI3-biallelic DCM2A counterpart was identified in dogs, cats, livestock, or wildlife, and there is no zoonotic or transmissible component. Orthologs are present across vertebrates, reflecting conservation of cardiac thin-filament regulation, but orthology alone does not establish a natural veterinary disease.

A major curation warning is that TNNI3K encodes cardiac troponin-I-interacting kinase, not cardiac troponin I. Cardiac-specific Tnni3k-knockout mice develop age-progressive dysfunction, dilation, hypertrophy, fibrosis, and apoptosis involving p38 MAPK, but this is not a DCM2A model and should not be annotated as TNNI3 evidence. (qu2022knockoutofcardiac pages 7-7)

15. Model organisms and experimental systems

No well-validated model reproducing human biallelic TNNI3-null DCM2A was identified in the retrieved literature. Relevant platforms for future work include:

  • Knock-in/knockout mice: suitable for chamber remodeling, hemodynamics, arrhythmia, and AAV replacement, but complete loss may cause developmental lethality and murine calcium/heart-rate physiology limits translation.
  • Zebrafish: rapid CRISPR modeling and live cardiac imaging are advantages; duplicated genes and two-chamber physiology are limitations.
  • Patient-derived or isogenic hiPSC cardiomyocytes: appropriate for sarcomere assembly, calcium transients, contractility, transcript rescue, and drug screening. Immaturity and fetal TNNI1 expression can obscure a disease whose biology depends on the developmental TNNI1-to-TNNI3 switch.
  • Engineered heart tissue/organoids: can quantify force and test gene replacement in a three-dimensional context, but do not reproduce whole-organ loading, immunity, conduction, or systemic failure.

Models of heterozygous TNNI3 missense cardiomyopathy can clarify troponin biology but cannot be assumed to model biallelic null disease. Likewise, TNNI3K models are non-equivalent. (sorrentino2023homozygoustnni3mutations pages 5-8, qu2022knockoutofcardiac pages 7-7)

Recent developments and authoritative interpretation

The key 2023 advance was consolidation of the claim that biallelic TNNI3 null variants cause a severe neonatal/infantile DCM, supported by two additional unrelated patients and a systematic review. The authors’ abstract states that “an increasing amount of evidence has validated the hypothesis that biallelic TNNI3 null mutations cause a severe form of neonatal dilated cardiomyopathy.” (sorrentino2023homozygoustnni3mutations pages 1-2)

Current 2024 genetic-DCM reviews emphasize that genetic testing is now integral to pediatric diagnosis, prognosis, and cascade screening, while warning that more than 200 genes have been associated with DCM but evidence is limited for many. For DCM2A, the causal claim is strongest when the phenotype is severe and early, variants are genuinely biallelic and loss-of-function, segregation is compatible, and population frequency is sufficiently low. (newman2024dilatedcardiomyopathya pages 1-2, eldemire2024geneticsofdilated pages 1-3, arnautu2024riskassessmentand pages 11-12)

The expert interpretation is therefore conservative: DCM2A is a credible but ultra-rare recessive troponinopathy with a compelling loss-of-function mechanism and severe natural history. Its immediate real-world applications are molecular diagnosis, rapid family testing, reproductive counseling, intensive presymptomatic surveillance, and early advanced-heart-failure referral. Disease-specific epidemiology, longitudinal quality-of-life data, multi-omics, validated models, and targeted therapy remain major unmet needs.

References

  1. (sorrentino2023homozygoustnni3mutations pages 8-9): Ugo Sorrentino, Ilaria Gabbiato, Chiara Canciani, Davide Calosci, Chiara Rigon, Daniela Zuccarello, and Matteo Cassina. Homozygous tnni3 mutations and severe early onset dilated cardiomyopathy: patient report and review of the literature. Genes, 14:748, Mar 2023. URL: https://doi.org/10.3390/genes14030748, doi:10.3390/genes14030748. This article has 19 citations.

  2. (sorrentino2023homozygoustnni3mutations pages 1-2): Ugo Sorrentino, Ilaria Gabbiato, Chiara Canciani, Davide Calosci, Chiara Rigon, Daniela Zuccarello, and Matteo Cassina. Homozygous tnni3 mutations and severe early onset dilated cardiomyopathy: patient report and review of the literature. Genes, 14:748, Mar 2023. URL: https://doi.org/10.3390/genes14030748, doi:10.3390/genes14030748. This article has 19 citations.

  3. (sorrentino2023homozygoustnni3mutations pages 2-4): Ugo Sorrentino, Ilaria Gabbiato, Chiara Canciani, Davide Calosci, Chiara Rigon, Daniela Zuccarello, and Matteo Cassina. Homozygous tnni3 mutations and severe early onset dilated cardiomyopathy: patient report and review of the literature. Genes, 14:748, Mar 2023. URL: https://doi.org/10.3390/genes14030748, doi:10.3390/genes14030748. This article has 19 citations.

  4. (newman2024dilatedcardiomyopathya pages 1-2): Noah A. Newman and Michael A. Burke. Dilated cardiomyopathy: a genetic journey from past to future. International Journal of Molecular Sciences, 25:11460, Oct 2024. URL: https://doi.org/10.3390/ijms252111460, doi:10.3390/ijms252111460. This article has 27 citations.

  5. (sorrentino2023homozygoustnni3mutations pages 5-8): Ugo Sorrentino, Ilaria Gabbiato, Chiara Canciani, Davide Calosci, Chiara Rigon, Daniela Zuccarello, and Matteo Cassina. Homozygous tnni3 mutations and severe early onset dilated cardiomyopathy: patient report and review of the literature. Genes, 14:748, Mar 2023. URL: https://doi.org/10.3390/genes14030748, doi:10.3390/genes14030748. This article has 19 citations.

  6. (eldemire2024geneticsofdilated pages 1-3): Ramone Eldemire, Luisa Mestroni, and Matthew R.G. Taylor. Genetics of dilated cardiomyopathy. Jan 2024. URL: https://doi.org/10.1146/annurev-med-052422-020535, doi:10.1146/annurev-med-052422-020535. This article has 79 citations and is from a domain leading peer-reviewed journal.

  7. (sorrentino2023homozygoustnni3mutations pages 4-5): Ugo Sorrentino, Ilaria Gabbiato, Chiara Canciani, Davide Calosci, Chiara Rigon, Daniela Zuccarello, and Matteo Cassina. Homozygous tnni3 mutations and severe early onset dilated cardiomyopathy: patient report and review of the literature. Genes, 14:748, Mar 2023. URL: https://doi.org/10.3390/genes14030748, doi:10.3390/genes14030748. This article has 19 citations.

  8. (arnautu2024riskassessmentand pages 11-12): Diana-Aurora Arnautu, Dragos Cozma, Ioan-Radu Lala, Sergiu-Florin Arnautu, Mirela-Cleopatra Tomescu, and Minodora Andor. Risk assessment and personalized treatment options in inherited dilated cardiomyopathies: a narrative review. Biomedicines, 12:1643, Jul 2024. URL: https://doi.org/10.3390/biomedicines12081643, doi:10.3390/biomedicines12081643. This article has 8 citations.

  9. (arnautu2024riskassessmentand pages 21-23): Diana-Aurora Arnautu, Dragos Cozma, Ioan-Radu Lala, Sergiu-Florin Arnautu, Mirela-Cleopatra Tomescu, and Minodora Andor. Risk assessment and personalized treatment options in inherited dilated cardiomyopathies: a narrative review. Biomedicines, 12:1643, Jul 2024. URL: https://doi.org/10.3390/biomedicines12081643, doi:10.3390/biomedicines12081643. This article has 8 citations.

  10. (mestroni2014geneticcausesof pages 6-8): Luisa Mestroni, Francesca Brun, Anita Spezzacatene, Gianfranco Sinagra, and Matthew R.G. Taylor. Genetic causes of dilated cardiomyopathy. Progress in pediatric cardiology, 37 1-2:13-18, Dec 2014. URL: https://doi.org/10.1016/j.ppedcard.2014.10.003, doi:10.1016/j.ppedcard.2014.10.003. This article has 143 citations and is from a peer-reviewed journal.

  11. (bondue2018complexroadsfrom pages 19-22): Antoine Bondue, Eloisa Arbustini, Anna Bianco, Michele Ciccarelli, Dana Dawson, Matteo De Rosa, Nazha Hamdani, Denise Hilfiker-Kleiner, Benjamin Meder, Adelino F Leite-Moreira, Thomas Thum, Carlo G Tocchetti, Gilda Varricchi, Jolanda Van der Velden, Roddy Walsh, and Stephane Heymans. Complex roads from genotype to phenotype in dilated cardiomyopathy: scientific update from the working group of myocardial function of the european society of cardiology. Cardiovascular Research, 114:1287–1303, Aug 2018. URL: https://doi.org/10.1093/cvr/cvy122, doi:10.1093/cvr/cvy122. This article has 138 citations and is from a domain leading peer-reviewed journal.

  12. (qu2022knockoutofcardiac pages 7-7): Hui-Lin Qu, Yue Zhang, Wei Zhang, Yaxin Zhu, and Rui-xia Xu. Knockout of cardiac troponin i‐interacting kinase leads to cardiac dysfunction and remodelling. Jul 2022. URL: https://doi.org/10.1111/1440-1681.13699, doi:10.1111/1440-1681.13699. This article has 3 citations and is from a peer-reviewed journal.

  13. (mestroni2014geneticcausesof pages 1-3): Luisa Mestroni, Francesca Brun, Anita Spezzacatene, Gianfranco Sinagra, and Matthew R.G. Taylor. Genetic causes of dilated cardiomyopathy. Progress in pediatric cardiology, 37 1-2:13-18, Dec 2014. URL: https://doi.org/10.1016/j.ppedcard.2014.10.003, doi:10.1016/j.ppedcard.2014.10.003. This article has 143 citations and is from a peer-reviewed journal.

Artifacts